{
 "cells": [
  {
   "cell_type": "code",
   "execution_count": 22,
   "id": "c4402fd3",
   "metadata": {},
   "outputs": [],
   "source": [
    "import os\n",
    "import time\n",
    "import math\n",
    "import json\n",
    "import re\n",
    "from typing import Any, Dict, List, Optional, Tuple\n",
    "\n",
    "import requests\n",
    "import pandas as pd\n",
    "from tqdm.auto import tqdm\n",
    "\n",
    "pd.set_option(\"display.max_colwidth\", 200)\n",
    "\n",
    "SESSION = requests.Session()\n",
    "SESSION.headers.update({\"User-Agent\": \"biotech-ingestion-exploration/0.1 (contact: your-email@example.com)\"})\n",
    "\n",
    "def _get(url: str, params: Optional[dict] = None, timeout: int = 30) -> dict:\n",
    "    r = SESSION.get(url, params=params, timeout=timeout)\n",
    "    r.raise_for_status()\n",
    "    # Most endpoints here are JSON; if not, we handle elsewhere.\n",
    "    return r.json()\n",
    "\n",
    "def pretty(obj: Any, max_len: int | None = None) -> None:\n",
    "    s = json.dumps(obj, indent=2, ensure_ascii=False) \n",
    "    if max_len: \n",
    "        s = s[:max_len]\n",
    "        print(s + (\"\\n... (truncated)\" if len(s) > max_len else \"\"))   \n",
    "    else:\n",
    "        print(s)\n",
    "\n",
    "def to_df(rows: List[dict], cols: Optional[List[str]] = None) -> pd.DataFrame:\n",
    "    df = pd.DataFrame(rows)\n",
    "    if cols:\n",
    "        for c in cols:\n",
    "            if c not in df.columns:\n",
    "                df[c] = None\n",
    "        df = df[cols]\n",
    "    return df"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 3,
   "id": "bdfb0f5c",
   "metadata": {},
   "outputs": [],
   "source": [
    "NCBI_BASE = \"https://eutils.ncbi.nlm.nih.gov/entrez/eutils\"\n",
    "\n",
    "def pubmed_esearch(query: str, retmax: int = 20, retstart: int = 0, api_key: Optional[str] = None) -> dict:\n",
    "    \"\"\"\n",
    "    Returns PubMed IDs for a query.\n",
    "    \"\"\"\n",
    "    params = {\n",
    "        \"db\": \"pubmed\",\n",
    "        \"term\": query,\n",
    "        \"retmode\": \"json\",\n",
    "        \"retmax\": retmax,\n",
    "        \"retstart\": retstart,\n",
    "        \"sort\": \"relevance\",\n",
    "    }\n",
    "    if api_key:\n",
    "        params[\"api_key\"] = api_key\n",
    "    return _get(f\"{NCBI_BASE}/esearch.fcgi\", params=params)\n",
    "\n",
    "def pubmed_esummary(pmids: List[str], api_key: Optional[str] = None) -> dict:\n",
    "    \"\"\"\n",
    "    Lightweight metadata for a list of PubMed IDs.\n",
    "    \"\"\"\n",
    "    params = {\n",
    "        \"db\": \"pubmed\",\n",
    "        \"id\": \",\".join(pmids),\n",
    "        \"retmode\": \"json\",\n",
    "    }\n",
    "    if api_key:\n",
    "        params[\"api_key\"] = api_key\n",
    "    return _get(f\"{NCBI_BASE}/esummary.fcgi\", params=params)\n",
    "\n",
    "def pubmed_efetch_xml(pmids: List[str], api_key: Optional[str] = None) -> str:\n",
    "    \"\"\"\n",
    "    Full PubMed record XML (useful for deep parsing of abstracts, MeSH, registry IDs, etc.)\n",
    "    \"\"\"\n",
    "    params = {\n",
    "        \"db\": \"pubmed\",\n",
    "        \"id\": \",\".join(pmids),\n",
    "        \"retmode\": \"xml\",\n",
    "    }\n",
    "    if api_key:\n",
    "        params[\"api_key\"] = api_key\n",
    "    r = SESSION.get(f\"{NCBI_BASE}/efetch.fcgi\", params=params, timeout=30)\n",
    "    r.raise_for_status()\n",
    "    return r.text\n",
    "\n",
    "def pubmed_search(query: str, n: int = 20, api_key: Optional[str] = None) -> pd.DataFrame:\n",
    "    \"\"\"\n",
    "    Convenience: run search + summary, return a tidy DataFrame.\n",
    "    \"\"\"\n",
    "    es = pubmed_esearch(query, retmax=n, api_key=api_key)\n",
    "    pmids = es.get(\"esearchresult\", {}).get(\"idlist\", [])\n",
    "    if not pmids:\n",
    "        return pd.DataFrame()\n",
    "    summ = pubmed_esummary(pmids, api_key=api_key)\n",
    "    result = summ.get(\"result\", {})\n",
    "    uids = result.get(\"uids\", [])\n",
    "    rows = []\n",
    "    for uid in uids:\n",
    "        item = result.get(uid, {})\n",
    "        rows.append({\n",
    "            \"pmid\": uid,\n",
    "            \"title\": item.get(\"title\"),\n",
    "            \"pubdate\": item.get(\"pubdate\"),\n",
    "            \"source\": item.get(\"source\"),  # journal\n",
    "            \"authors\": \", \".join([a.get(\"name\",\"\") for a in item.get(\"authors\", []) if a.get(\"name\")]),\n",
    "            \"doi\": next((x.get(\"value\") for x in item.get(\"articleids\", []) if x.get(\"idtype\") == \"doi\"), None),\n",
    "        })\n",
    "    return pd.DataFrame(rows)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 4,
   "id": "e06ec96d",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>pmid</th>\n",
       "      <th>title</th>\n",
       "      <th>pubdate</th>\n",
       "      <th>source</th>\n",
       "      <th>authors</th>\n",
       "      <th>doi</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>28325349</td>\n",
       "      <td>Nanocrystalline cellulose-fullerene: Novel conjugates.</td>\n",
       "      <td>2017 May 15</td>\n",
       "      <td>Carbohydr Polym</td>\n",
       "      <td>Herreros-López A, Carini M, Da Ros T, Carofiglio T, Marega C, La Parola V, Rapozzi V, Xodo LE, Alshatwi AA, Hadad C, Prato M</td>\n",
       "      <td>10.1016/j.carbpol.2017.01.068</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>17309168</td>\n",
       "      <td>Fullerenes in biomedicine.</td>\n",
       "      <td>2006 Oct-Dec</td>\n",
       "      <td>J BUON</td>\n",
       "      <td>Djordjević A, Bogdanović G, Dobrić S</td>\n",
       "      <td>None</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>21413269</td>\n",
       "      <td>Mycobacteria and Nocardia.</td>\n",
       "      <td>1996</td>\n",
       "      <td></td>\n",
       "      <td>Baron S, McMurray DN</td>\n",
       "      <td>None</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>35051749</td>\n",
       "      <td>Synthesis and biological application of glyco- and peptide derivatives of fullerene C(60).</td>\n",
       "      <td>2022 Feb 15</td>\n",
       "      <td>Eur J Med Chem</td>\n",
       "      <td>Tanzi L, Terreni M, Zhang Y</td>\n",
       "      <td>10.1016/j.ejmech.2022.114104</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>18217343</td>\n",
       "      <td>Toxicity studies of fullerenes and derivatives.</td>\n",
       "      <td>2007</td>\n",
       "      <td>Adv Exp Med Biol</td>\n",
       "      <td>Kolosnjaj J, Szwarc H, Moussa F</td>\n",
       "      <td>10.1007/978-0-387-76713-0_13</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>5</th>\n",
       "      <td>38744728</td>\n",
       "      <td>Efficient detection of nitric oxide a biomarker associated with COVID19 via N, P co-doped C(60) fullerene: a computational study.</td>\n",
       "      <td>2024 May 14</td>\n",
       "      <td>J Mol Model</td>\n",
       "      <td>Khan AA, Ahmad R, Mehmood F, Ahmad I</td>\n",
       "      <td>10.1007/s00894-024-05954-9</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>6</th>\n",
       "      <td>36643955</td>\n",
       "      <td>Anti-Inflammatory and Antioxidant Effects of Liposoluble C60 at the Cellular, Molecular, and Whole-Animal Levels.</td>\n",
       "      <td>2023</td>\n",
       "      <td>J Inflamm Res</td>\n",
       "      <td>Hui M, Jia X, Li X, Lazcano-Silveira R, Shi M</td>\n",
       "      <td>10.2147/JIR.S386381</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>7</th>\n",
       "      <td>35110453</td>\n",
       "      <td>[Development of Bio-active Fullerene Derivatives Suitable for Drug].</td>\n",
       "      <td>2022</td>\n",
       "      <td>Yakugaku Zasshi</td>\n",
       "      <td>Mashino T</td>\n",
       "      <td>10.1248/yakushi.21-00188</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>8</th>\n",
       "      <td>31765863</td>\n",
       "      <td>Advances in the application, toxicity and degradation of carbon nanomaterials in environment: A review.</td>\n",
       "      <td>2020 Jan</td>\n",
       "      <td>Environ Int</td>\n",
       "      <td>Peng Z, Liu X, Zhang W, Zeng Z, Liu Z, Zhang C, Liu Y, Shao B, Liang Q, Tang W, Yuan X</td>\n",
       "      <td>10.1016/j.envint.2019.105298</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>9</th>\n",
       "      <td>19886744</td>\n",
       "      <td>Role of oxidative damage in toxicity of particulates.</td>\n",
       "      <td>2010 Jan</td>\n",
       "      <td>Free Radic Res</td>\n",
       "      <td>Møller P, Jacobsen NR, Folkmann JK, Danielsen PH, Mikkelsen L, Hemmingsen JG, Vesterdal LK, Forchhammer L, Wallin H, Loft S</td>\n",
       "      <td>10.3109/10715760903300691</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "       pmid  \\\n",
       "0  28325349   \n",
       "1  17309168   \n",
       "2  21413269   \n",
       "3  35051749   \n",
       "4  18217343   \n",
       "5  38744728   \n",
       "6  36643955   \n",
       "7  35110453   \n",
       "8  31765863   \n",
       "9  19886744   \n",
       "\n",
       "                                                                                                                               title  \\\n",
       "0                                                                             Nanocrystalline cellulose-fullerene: Novel conjugates.   \n",
       "1                                                                                                         Fullerenes in biomedicine.   \n",
       "2                                                                                                         Mycobacteria and Nocardia.   \n",
       "3                                         Synthesis and biological application of glyco- and peptide derivatives of fullerene C(60).   \n",
       "4                                                                                    Toxicity studies of fullerenes and derivatives.   \n",
       "5  Efficient detection of nitric oxide a biomarker associated with COVID19 via N, P co-doped C(60) fullerene: a computational study.   \n",
       "6                  Anti-Inflammatory and Antioxidant Effects of Liposoluble C60 at the Cellular, Molecular, and Whole-Animal Levels.   \n",
       "7                                                               [Development of Bio-active Fullerene Derivatives Suitable for Drug].   \n",
       "8                            Advances in the application, toxicity and degradation of carbon nanomaterials in environment: A review.   \n",
       "9                                                                              Role of oxidative damage in toxicity of particulates.   \n",
       "\n",
       "        pubdate            source  \\\n",
       "0   2017 May 15   Carbohydr Polym   \n",
       "1  2006 Oct-Dec            J BUON   \n",
       "2          1996                     \n",
       "3   2022 Feb 15    Eur J Med Chem   \n",
       "4          2007  Adv Exp Med Biol   \n",
       "5   2024 May 14       J Mol Model   \n",
       "6          2023     J Inflamm Res   \n",
       "7          2022   Yakugaku Zasshi   \n",
       "8      2020 Jan       Environ Int   \n",
       "9      2010 Jan    Free Radic Res   \n",
       "\n",
       "                                                                                                                        authors  \\\n",
       "0  Herreros-López A, Carini M, Da Ros T, Carofiglio T, Marega C, La Parola V, Rapozzi V, Xodo LE, Alshatwi AA, Hadad C, Prato M   \n",
       "1                                                                                          Djordjević A, Bogdanović G, Dobrić S   \n",
       "2                                                                                                          Baron S, McMurray DN   \n",
       "3                                                                                                   Tanzi L, Terreni M, Zhang Y   \n",
       "4                                                                                               Kolosnjaj J, Szwarc H, Moussa F   \n",
       "5                                                                                          Khan AA, Ahmad R, Mehmood F, Ahmad I   \n",
       "6                                                                                 Hui M, Jia X, Li X, Lazcano-Silveira R, Shi M   \n",
       "7                                                                                                                     Mashino T   \n",
       "8                                        Peng Z, Liu X, Zhang W, Zeng Z, Liu Z, Zhang C, Liu Y, Shao B, Liang Q, Tang W, Yuan X   \n",
       "9   Møller P, Jacobsen NR, Folkmann JK, Danielsen PH, Mikkelsen L, Hemmingsen JG, Vesterdal LK, Forchhammer L, Wallin H, Loft S   \n",
       "\n",
       "                             doi  \n",
       "0  10.1016/j.carbpol.2017.01.068  \n",
       "1                           None  \n",
       "2                           None  \n",
       "3   10.1016/j.ejmech.2022.114104  \n",
       "4   10.1007/978-0-387-76713-0_13  \n",
       "5     10.1007/s00894-024-05954-9  \n",
       "6            10.2147/JIR.S386381  \n",
       "7       10.1248/yakushi.21-00188  \n",
       "8   10.1016/j.envint.2019.105298  \n",
       "9      10.3109/10715760903300691  "
      ]
     },
     "execution_count": 4,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "pubmed_query = '(\"carbon 60\"[TIAB] OR C60[TIAB] OR buckminsterfullerene[TIAB]) AND (human*[TIAB] OR trial[TIAB] OR \"case report\"[PT])'\n",
    "df_pubmed = pubmed_search(pubmed_query, n=10)\n",
    "df_pubmed"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 5,
   "id": "fafb2767",
   "metadata": {},
   "outputs": [],
   "source": [
    "EPMC_BASE = \"https://www.ebi.ac.uk/europepmc/webservices/rest\"\n",
    "\n",
    "def epmc_search(query: str, page_size: int = 20, cursor_mark: str = \"*\", sort: str = \"RELEVANCE\") -> dict:\n",
    "    \"\"\"\n",
    "    Europe PMC search with cursor-based pagination.\n",
    "    sort options include: RELEVANCE, DATE, CITED\n",
    "    \"\"\"\n",
    "    # format: https://.../search?query=...&format=json&pageSize=...&cursorMark=...\n",
    "    params = {\n",
    "        \"query\": query,\n",
    "        \"format\": \"json\",\n",
    "        \"pageSize\": page_size,\n",
    "        \"cursorMark\": cursor_mark,\n",
    "        \"sort\": sort,\n",
    "    }\n",
    "    return _get(f\"{EPMC_BASE}/search\", params=params)\n",
    "\n",
    "def epmc_search_df(query: str, n: int = 20, sort: str = \"RELEVANCE\") -> pd.DataFrame:\n",
    "    \"\"\"\n",
    "    Fetch up to n results into a DataFrame.\n",
    "    \"\"\"\n",
    "    rows = []\n",
    "    cursor = \"*\"\n",
    "    while len(rows) < n:\n",
    "        data = epmc_search(query=query, page_size=min(100, n - len(rows)), cursor_mark=cursor, sort=sort)\n",
    "        hits = data.get(\"resultList\", {}).get(\"result\", []) or []\n",
    "        if not hits:\n",
    "            break\n",
    "        for h in hits:\n",
    "            rows.append({\n",
    "                \"source\": h.get(\"source\"),\n",
    "                \"id\": h.get(\"id\"),\n",
    "                \"pmid\": h.get(\"pmid\"),\n",
    "                \"pmcid\": h.get(\"pmcid\"),\n",
    "                \"doi\": h.get(\"doi\"),\n",
    "                \"title\": h.get(\"title\"),\n",
    "                \"pubYear\": h.get(\"pubYear\"),\n",
    "                \"journalTitle\": h.get(\"journalTitle\"),\n",
    "                \"authorString\": h.get(\"authorString\"),\n",
    "                \"isOpenAccess\": h.get(\"isOpenAccess\"),\n",
    "                \"pubType\": h.get(\"pubType\"),\n",
    "                \"citedByCount\": h.get(\"citedByCount\"),\n",
    "            })\n",
    "        cursor = data.get(\"nextCursorMark\")\n",
    "        if not cursor:\n",
    "            break\n",
    "    return pd.DataFrame(rows)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 6,
   "id": "c194878e",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "Empty DataFrame\n",
       "Columns: []\n",
       "Index: []"
      ]
     },
     "execution_count": 6,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "# --- Cell 6: Europe PMC test ---\n",
    "epmc_query = '(C60 OR \"carbon 60\" OR buckminsterfullerene) AND (longevity OR \"oxidative stress\" OR mitochondria OR \"case report\")'\n",
    "df_epmc = epmc_search_df(epmc_query, n=15, sort=\"DATE\")\n",
    "df_epmc\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 13,
   "id": "c7342244",
   "metadata": {},
   "outputs": [],
   "source": [
    "# --- Cell 7: ClinicalTrials.gov v2 client ---\n",
    "CTG_BASE = \"https://clinicaltrials.gov/api/v2\"\n",
    "\n",
    "def ctg_get(url: str, params: Optional[dict] = None, timeout: int = 30) -> dict:\n",
    "    r = SESSION.get(url, params=params, timeout=timeout)  # uses your existing SESSION\n",
    "    if r.status_code == 400:\n",
    "        # Make debugging easy in notebooks\n",
    "        raise requests.HTTPError(f\"400 Bad Request\\nURL: {r.url}\\nBody: {r.text[:1000]}\", response=r)\n",
    "    r.raise_for_status()\n",
    "    return r.json()\n",
    "\n",
    "def ctg_field_ok(field_name: str) -> bool:\n",
    "    \"\"\"\n",
    "    Checks if a single field name is valid by calling the v2 stats endpoint.\n",
    "    If invalid, CTG generally 400s.\n",
    "    \"\"\"\n",
    "    url = f\"{CTG_BASE}/stats/field/values\"\n",
    "    try:\n",
    "        _ = ctg_get(url, params={\"fields\": field_name})\n",
    "        return True\n",
    "    except requests.HTTPError:\n",
    "        return False\n",
    "\n",
    "def ctg_validate_fields(fields: List[str]) -> Dict[str, bool]:\n",
    "    \"\"\"\n",
    "    Returns {field: True/False} for validity.\n",
    "    \"\"\"\n",
    "    return {f: ctg_field_ok(f) for f in fields}\n",
    "\n",
    "# A conservative list of fields that are commonly valid piece names.\n",
    "# (Start minimal; add more only after validating.)\n",
    "CTG_MIN_FIELDS = [\n",
    "    \"NCTId\",\n",
    "    \"BriefTitle\",\n",
    "    \"OfficialTitle\",\n",
    "    \"OverallStatus\",\n",
    "    \"StudyType\",\n",
    "    \"Phase\",\n",
    "    \"EnrollmentCount\",\n",
    "    \"LeadSponsorName\",\n",
    "    # \"Conditions\", \n",
    "    # Invalid \n",
    "   # Interventions \n",
    "   # Invalid \n",
    "    \"StartDate\",\n",
    "    \"CompletionDate\",\n",
    "]\n",
    "\n",
    "def ctg_search(query_term: str, page_size: int = 20, page_token: Optional[str] = None,\n",
    "               fields: Optional[List[str]] = None) -> dict:\n",
    "    params = {\n",
    "        \"query.term\": query_term,\n",
    "        \"pageSize\": page_size,\n",
    "    }\n",
    "    if page_token:\n",
    "        params[\"pageToken\"] = page_token\n",
    "    if fields:\n",
    "        params[\"fields\"] = \",\".join(fields)\n",
    "    return ctg_get(f\"{CTG_BASE}/studies\", params=params)\n",
    "\n",
    "def ctg_search_df(query_term: str, n: int = 50, fields: Optional[List[str]] = None) -> pd.DataFrame:\n",
    "    \"\"\"\n",
    "    Light surface table from CTG. If fields is None, uses CTG_MIN_FIELDS.\n",
    "    \"\"\"\n",
    "    fields = fields or CTG_MIN_FIELDS\n",
    "\n",
    "    rows = []\n",
    "    token = None\n",
    "    while len(rows) < n:\n",
    "        data = ctg_search(query_term, page_size=min(100, n - len(rows)), page_token=token, fields=fields)\n",
    "        studies = data.get(\"studies\") or []\n",
    "        for s in studies:\n",
    "            p = s.get(\"protocolSection\", {})\n",
    "            ident = p.get(\"identificationModule\", {})\n",
    "            status = p.get(\"statusModule\", {})\n",
    "            design = p.get(\"designModule\", {})\n",
    "            sponsor = p.get(\"sponsorsModule\", {})\n",
    "            cond = p.get(\"conditionsModule\", {})\n",
    "            arms = p.get(\"armsInterventionsModule\", {})\n",
    "\n",
    "            interventions = arms.get(\"interventions\") or []\n",
    "            phases = design.get(\"phases\") or []\n",
    "            enrollment = (design.get(\"enrollmentInfo\") or {}).get(\"count\")\n",
    "\n",
    "            rows.append({\n",
    "                \"nctId\": ident.get(\"nctId\"),\n",
    "                \"briefTitle\": ident.get(\"briefTitle\"),\n",
    "                \"officialTitle\": ident.get(\"officialTitle\"),\n",
    "                \"overallStatus\": status.get(\"overallStatus\"),\n",
    "                \"studyType\": design.get(\"studyType\"),\n",
    "                \"phases\": \", \".join(phases) if phases else None,\n",
    "                \"enrollment\": enrollment,\n",
    "                \"leadSponsor\": (sponsor.get(\"leadSponsor\") or {}).get(\"name\"),\n",
    "                \"conditions\": \"; \".join(cond.get(\"conditions\") or []),\n",
    "                \"interventions\": \"; \".join([i.get(\"name\",\"\") for i in interventions if i.get(\"name\")]),\n",
    "                \"startDate\": (status.get(\"startDateStruct\") or {}).get(\"date\"),\n",
    "                \"completionDate\": (status.get(\"completionDateStruct\") or {}).get(\"date\"),\n",
    "            })\n",
    "\n",
    "        token = data.get(\"nextPageToken\")\n",
    "        if not token or not studies:\n",
    "            break\n",
    "\n",
    "    return pd.DataFrame(rows)\n",
    "\n",
    "def ctg_get_study(nct_id: str) -> dict:\n",
    "    return ctg_get(f\"{CTG_BASE}/studies/{nct_id}\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 14,
   "id": "29cd9420",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>nctId</th>\n",
       "      <th>briefTitle</th>\n",
       "      <th>officialTitle</th>\n",
       "      <th>overallStatus</th>\n",
       "      <th>studyType</th>\n",
       "      <th>phases</th>\n",
       "      <th>enrollment</th>\n",
       "      <th>leadSponsor</th>\n",
       "      <th>conditions</th>\n",
       "      <th>interventions</th>\n",
       "      <th>startDate</th>\n",
       "      <th>completionDate</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>NCT01213043</td>\n",
       "      <td>Safety and Pharmacokinetics of Alpha-1 Proteinase Inhibitor in Subjects With Alpha1-Antitrypsin Deficiency</td>\n",
       "      <td>A Randomized Double-blind Crossover Study to Assess the Safety and Pharmacokinetics of Two Different Doses of Weekly Intravenous Administration of Alpha1-Proteinase Inhibitor (Human) Prolastin®-C ...</td>\n",
       "      <td>COMPLETED</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "      <td>PHASE2</td>\n",
       "      <td>30</td>\n",
       "      <td>None</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>2010-11</td>\n",
       "      <td>2012-01</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>NCT03776175</td>\n",
       "      <td>A Study To Assess Pharmacodynamics, Safety And Tolerability Of PF-05221304 And PF-06865571 Co-Administered For 6 Weeks In Adults With Non-Alcoholic Fatty Liver Disease.</td>\n",
       "      <td>A PHASE 2A, RANDOMIZED, DOUBLE BLIND (SPONSOR-OPEN), PLACEBO CONTROLLED, PARALLEL GROUP STUDY TO ASSESS THE PHARMACODYNAMICS, SAFETY AND TOLERABILITY OF PF-05221304 AND PF-06865571 CO-ADMINISTERED...</td>\n",
       "      <td>COMPLETED</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "      <td>PHASE2</td>\n",
       "      <td>99</td>\n",
       "      <td>None</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>2019-01-04</td>\n",
       "      <td>2019-10-11</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>NCT01934192</td>\n",
       "      <td>Nutritional Adequacy Therapeutic Enhancement in the Critically Ill. The NUTRIATE Study</td>\n",
       "      <td>NUTRItional Adequacy Therapeutic Enhancement in the Critically Ill: A Randomized Double Blind, Placebo-controlled Trial of the Motilin Receptor Agonist GSK962040. The NUTRIATE Study</td>\n",
       "      <td>TERMINATED</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "      <td>PHASE2</td>\n",
       "      <td>91</td>\n",
       "      <td>None</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>2014-04-04</td>\n",
       "      <td>2016-07-08</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>NCT00584324</td>\n",
       "      <td>Depth of Anesthesia on Implicit Memory</td>\n",
       "      <td>The Effect of Depth of Anesthesia on Implicit Memory</td>\n",
       "      <td>COMPLETED</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "      <td>NA</td>\n",
       "      <td>70</td>\n",
       "      <td>None</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>2006-03</td>\n",
       "      <td>2012-01</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>NCT06968208</td>\n",
       "      <td>The Efficacy and Safety of Puerarin in Obesity Treatment</td>\n",
       "      <td>Randomized Controlled Trial of Puerarin for Obesity Treatment</td>\n",
       "      <td>NOT_YET_RECRUITING</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "      <td>PHASE2</td>\n",
       "      <td>80</td>\n",
       "      <td>None</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>2025-08-01</td>\n",
       "      <td>2029-12-31</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>5</th>\n",
       "      <td>NCT05298202</td>\n",
       "      <td>The Influence of Capsaicin Gel During Exercise Within the Heat</td>\n",
       "      <td>The Influence of Topical Capsaicin on Thermoregulatory and Perceptual Outcomes During Exercise Within the Heat</td>\n",
       "      <td>COMPLETED</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "      <td>PHASE4</td>\n",
       "      <td>12</td>\n",
       "      <td>None</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>2022-05-25</td>\n",
       "      <td>2022-10-01</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>6</th>\n",
       "      <td>NCT05096065</td>\n",
       "      <td>Study to Evaluate the Pharmacodynamics and Efficacy of Leuprolide Tablets (Ovarest®) in Women With Endometriosis</td>\n",
       "      <td>An Open-label Dose-finding Study to Evaluate the Pharmacodynamic (PD) Profiles and Efficacy of Different Dosing Regimens of Leuprolide Oral Tablets (Ovarest®) in Women With Endometriosis</td>\n",
       "      <td>UNKNOWN</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "      <td>PHASE2</td>\n",
       "      <td>16</td>\n",
       "      <td>None</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>2022-03-18</td>\n",
       "      <td>2022-05</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>7</th>\n",
       "      <td>NCT00664742</td>\n",
       "      <td>The Effect of Fluvastatin XL® Treatment in Patients With Metabolic Syndrome</td>\n",
       "      <td>The Effect Of Fluvastatin XL® Treatment On The Lipid Profile In Patients With Metabolic Syndrome</td>\n",
       "      <td>COMPLETED</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "      <td>PHASE4</td>\n",
       "      <td>614</td>\n",
       "      <td>None</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>2006-09</td>\n",
       "      <td>2007-10</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>8</th>\n",
       "      <td>NCT02083068</td>\n",
       "      <td>Evaluation of the Protective Efficacy of a Vaccine Derived From the Synthetic CS Protein of Plasmodium Vivax</td>\n",
       "      <td>Evaluation of the Protective Efficacy of a Vaccine Derived From the Synthetic CS Protein of Plasmodium Vivax</td>\n",
       "      <td>COMPLETED</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "      <td>PHASE2</td>\n",
       "      <td>32</td>\n",
       "      <td>None</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>2014-08</td>\n",
       "      <td>2017-07</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>9</th>\n",
       "      <td>NCT07181733</td>\n",
       "      <td>BNP in Pediatric Metabolic Syndrome</td>\n",
       "      <td>Exploring B-Type Natriuretic Peptide (BNP) Evolution, From the Neonatal to Adolescent Period, as a Tool to Early Identify the Risk for Metabolic Syndrome (MetS) in a Former Preterm and Full Term A...</td>\n",
       "      <td>RECRUITING</td>\n",
       "      <td>OBSERVATIONAL</td>\n",
       "      <td>None</td>\n",
       "      <td>70</td>\n",
       "      <td>None</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>2024-05-08</td>\n",
       "      <td>2025-12-31</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>10</th>\n",
       "      <td>NCT06054919</td>\n",
       "      <td>The Effect of Vitamin D3 Therapy on Vitamin D Status in Pregnant Women With Vitamin D Deficient and Insufficient</td>\n",
       "      <td>The Effect of Vitamin D3 Therapy on 25(OH)D, 1,25(OH)2D, VDBP, and 24,25(OH)2D Maternal Serum Levels in Pregnant Women With Vitamin D Deficient and Insufficient</td>\n",
       "      <td>UNKNOWN</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "      <td>PHASE2, PHASE3</td>\n",
       "      <td>52</td>\n",
       "      <td>None</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>2021-04-01</td>\n",
       "      <td>2023-11-30</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>11</th>\n",
       "      <td>NCT02282527</td>\n",
       "      <td>A Study to Assess Safety and PK of Liquid Alpha₁-Proteinase Inhibitor (Human) in Treating Alpha₁-Antitrypsin Deficiency</td>\n",
       "      <td>A Multi-center, Randomized, Double-blind, Crossover Study to Assess the Safety and Pharmacokinetics of Liquid Alpha₁-Proteinase Inhibitor (Human) Compared to Prolastin®-C in Subjects With Alpha₁-A...</td>\n",
       "      <td>COMPLETED</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "      <td>PHASE2, PHASE3</td>\n",
       "      <td>32</td>\n",
       "      <td>None</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>2014-10</td>\n",
       "      <td>2016-01</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>12</th>\n",
       "      <td>NCT06124820</td>\n",
       "      <td>RCT Comparing Intravaginal Laser Therapy to Sham in Post-menopausal Women with Recurrent Urinary Tract Infections</td>\n",
       "      <td>A Single-blinded, Randomised Controlled Trial Comparing the Use of Intravaginal Laser Therapy to Sham in Post-menopausal Women with Recurrent Urinary Tract Infections (rUTI) and the Impact on the ...</td>\n",
       "      <td>ACTIVE_NOT_RECRUITING</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "      <td>NA</td>\n",
       "      <td>48</td>\n",
       "      <td>None</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>2023-10-01</td>\n",
       "      <td>2026-10-08</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>13</th>\n",
       "      <td>NCT00535912</td>\n",
       "      <td>Phase III Study Treatment of CLL B and C</td>\n",
       "      <td>A Multicentric Phase III Study in Patients With CLL B and C &lt; 60 Years Not Treated: 6 Montly CHOP + 6 CHOP Every 3 Months Versus 3 Montly CHOP + Intensification and Autograft</td>\n",
       "      <td>COMPLETED</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "      <td>PHASE3</td>\n",
       "      <td>140</td>\n",
       "      <td>None</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>1999-01</td>\n",
       "      <td>2006-03</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>14</th>\n",
       "      <td>NCT04847570</td>\n",
       "      <td>The Effect of Music on Patients in Critical Care</td>\n",
       "      <td>The Effect of Music on Patients in Critical Care (EMPIRE)</td>\n",
       "      <td>UNKNOWN</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "      <td>NA</td>\n",
       "      <td>30</td>\n",
       "      <td>None</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>2021-04-13</td>\n",
       "      <td>2021-10-04</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>15</th>\n",
       "      <td>NCT06448182</td>\n",
       "      <td>Effect of a Postbiotic Intake on Glucose Control and Microbiota Composition of Type 2 Diabetic Subjects: a Randomized Controlled Trial.</td>\n",
       "      <td>Precision Medicine Against Type 2 Diabetes: Genetic Prediction and Nutritional Intervention With Postbiotics to Modulate Microbiota.</td>\n",
       "      <td>RECRUITING</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "      <td>NA</td>\n",
       "      <td>158</td>\n",
       "      <td>None</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>2025-01-09</td>\n",
       "      <td>2025-12-20</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>16</th>\n",
       "      <td>NCT04382963</td>\n",
       "      <td>Stroke Prevention in the Wisconsin Native American Population</td>\n",
       "      <td>Stroke Prevention in the Wisconsin Native American Population</td>\n",
       "      <td>COMPLETED</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "      <td>NA</td>\n",
       "      <td>120</td>\n",
       "      <td>None</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>2021-04-14</td>\n",
       "      <td>2025-10-01</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>17</th>\n",
       "      <td>NCT02614534</td>\n",
       "      <td>Clinical Trial to Evaluate Safety and Efficacy of Hyperthermic Intra-peritoneal Chemotherapy (HIPEC) With Mitomycin C Used During Surgery for Treatment of Locally Advanced Colorectal Carcinoma</td>\n",
       "      <td>Multicentre, Randomized Clinical Trial to Evaluate Safety and Efficacy of Hyperthermic Intra-peritoneal Chemotherapy (HIPEC) With Mitomycin C Used During Surgery for Treatment of Locally Advanced ...</td>\n",
       "      <td>UNKNOWN</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "      <td>PHASE3</td>\n",
       "      <td>200</td>\n",
       "      <td>None</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>2015-11-16</td>\n",
       "      <td>2024-03</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>18</th>\n",
       "      <td>NCT03840044</td>\n",
       "      <td>The Effect of Physical Exercise in a Cold Air Environment on Normal Volunteers and Asthmatic Patients</td>\n",
       "      <td>The Effect of Physical Exercise in a Cold Air Environment on Normal Volunteers and Asthmatic Patients</td>\n",
       "      <td>COMPLETED</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "      <td>NA</td>\n",
       "      <td>45</td>\n",
       "      <td>None</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>2019-06-03</td>\n",
       "      <td>2020-05-30</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>19</th>\n",
       "      <td>NCT01584258</td>\n",
       "      <td>Prostate Advances in Comparative Evidence</td>\n",
       "      <td>International Randomised Study of Prostatectomy vs Stereotactic Body Radiotherapy (SBRT) and Conventionally Fractionated Radiotherapy vs SBRT for Organ-Confined Prostate Cancer</td>\n",
       "      <td>ACTIVE_NOT_RECRUITING</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "      <td>PHASE3</td>\n",
       "      <td>2205</td>\n",
       "      <td>None</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>2012-08-07</td>\n",
       "      <td>2027-12</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>20</th>\n",
       "      <td>NCT03292926</td>\n",
       "      <td>A Novel Analgesia Technique for ACL Reconstruction</td>\n",
       "      <td>A Randomized Controlled Trial to Evaluate a Novel Analgesia Technique for ACL Reconstruction: Adductor Canal Block With an IPACK Versus Adductor Canal Block</td>\n",
       "      <td>COMPLETED</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "      <td>PHASE4</td>\n",
       "      <td>78</td>\n",
       "      <td>None</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>2017-10-04</td>\n",
       "      <td>2020-04-16</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>21</th>\n",
       "      <td>NCT02378246</td>\n",
       "      <td>Swedish Iodine in Pregnancy and Development in Children (SWIDDICH) Study</td>\n",
       "      <td>The Importance of Iodine During Pregnancy for Future Brain Function : a Randomized Placebo-controlled Trial. Swedish Iodine in Pregnancy and Development in Children (SWIDDICH) Study</td>\n",
       "      <td>ACTIVE_NOT_RECRUITING</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "      <td>NA</td>\n",
       "      <td>1337</td>\n",
       "      <td>None</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>2012-11</td>\n",
       "      <td>2032-06</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>22</th>\n",
       "      <td>NCT04141072</td>\n",
       "      <td>Shrunken Pore Syndrome: a Retrospective, Single Center, Cohort Study</td>\n",
       "      <td>Shrunken Pore Syndrome's Effect on Mortality in Elective Cardiac Surgery</td>\n",
       "      <td>COMPLETED</td>\n",
       "      <td>OBSERVATIONAL</td>\n",
       "      <td>None</td>\n",
       "      <td>4719</td>\n",
       "      <td>None</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>2010-01-01</td>\n",
       "      <td>2019-01-10</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>23</th>\n",
       "      <td>NCT04107454</td>\n",
       "      <td>Effect of Treatment With the Ablative Fractional Carbodioxide Laser in Vulvar Lichen Sclerosis</td>\n",
       "      <td>Effect of Treatment With the Ablative Fractional Carbodioxide Laser in Vulvar Lichen Sclerosis</td>\n",
       "      <td>UNKNOWN</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "      <td>NA</td>\n",
       "      <td>64</td>\n",
       "      <td>None</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>2020-01-01</td>\n",
       "      <td>2021-12</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>24</th>\n",
       "      <td>NCT06011967</td>\n",
       "      <td>Intubation with Different Angled Intubation Tubes Using C-macr D Blade Videolaringoscope;</td>\n",
       "      <td>Intubation with Different Angled Intubation Tubes Using C-macr D Blade Videolaringoscope; Evaluation of the Effect on Post-operative Sore Throat, Ease and Time of Intubation, Hoarseness, Subglotti...</td>\n",
       "      <td>COMPLETED</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "      <td>NA</td>\n",
       "      <td>54</td>\n",
       "      <td>None</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>2021-03-15</td>\n",
       "      <td>2022-06-13</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "          nctId  \\\n",
       "0   NCT01213043   \n",
       "1   NCT03776175   \n",
       "2   NCT01934192   \n",
       "3   NCT00584324   \n",
       "4   NCT06968208   \n",
       "5   NCT05298202   \n",
       "6   NCT05096065   \n",
       "7   NCT00664742   \n",
       "8   NCT02083068   \n",
       "9   NCT07181733   \n",
       "10  NCT06054919   \n",
       "11  NCT02282527   \n",
       "12  NCT06124820   \n",
       "13  NCT00535912   \n",
       "14  NCT04847570   \n",
       "15  NCT06448182   \n",
       "16  NCT04382963   \n",
       "17  NCT02614534   \n",
       "18  NCT03840044   \n",
       "19  NCT01584258   \n",
       "20  NCT03292926   \n",
       "21  NCT02378246   \n",
       "22  NCT04141072   \n",
       "23  NCT04107454   \n",
       "24  NCT06011967   \n",
       "\n",
       "                                                                                                                                                                                          briefTitle  \\\n",
       "0                                                                                         Safety and Pharmacokinetics of Alpha-1 Proteinase Inhibitor in Subjects With Alpha1-Antitrypsin Deficiency   \n",
       "1                           A Study To Assess Pharmacodynamics, Safety And Tolerability Of PF-05221304 And PF-06865571 Co-Administered For 6 Weeks In Adults With Non-Alcoholic Fatty Liver Disease.   \n",
       "2                                                                                                             Nutritional Adequacy Therapeutic Enhancement in the Critically Ill. The NUTRIATE Study   \n",
       "3                                                                                                                                                             Depth of Anesthesia on Implicit Memory   \n",
       "4                                                                                                                                           The Efficacy and Safety of Puerarin in Obesity Treatment   \n",
       "5                                                                                                                                     The Influence of Capsaicin Gel During Exercise Within the Heat   \n",
       "6                                                                                   Study to Evaluate the Pharmacodynamics and Efficacy of Leuprolide Tablets (Ovarest®) in Women With Endometriosis   \n",
       "7                                                                                                                        The Effect of Fluvastatin XL® Treatment in Patients With Metabolic Syndrome   \n",
       "8                                                                                       Evaluation of the Protective Efficacy of a Vaccine Derived From the Synthetic CS Protein of Plasmodium Vivax   \n",
       "9                                                                                                                                                                BNP in Pediatric Metabolic Syndrome   \n",
       "10                                                                                  The Effect of Vitamin D3 Therapy on Vitamin D Status in Pregnant Women With Vitamin D Deficient and Insufficient   \n",
       "11                                                                           A Study to Assess Safety and PK of Liquid Alpha₁-Proteinase Inhibitor (Human) in Treating Alpha₁-Antitrypsin Deficiency   \n",
       "12                                                                                 RCT Comparing Intravaginal Laser Therapy to Sham in Post-menopausal Women with Recurrent Urinary Tract Infections   \n",
       "13                                                                                                                                                          Phase III Study Treatment of CLL B and C   \n",
       "14                                                                                                                                                  The Effect of Music on Patients in Critical Care   \n",
       "15                                                           Effect of a Postbiotic Intake on Glucose Control and Microbiota Composition of Type 2 Diabetic Subjects: a Randomized Controlled Trial.   \n",
       "16                                                                                                                                     Stroke Prevention in the Wisconsin Native American Population   \n",
       "17  Clinical Trial to Evaluate Safety and Efficacy of Hyperthermic Intra-peritoneal Chemotherapy (HIPEC) With Mitomycin C Used During Surgery for Treatment of Locally Advanced Colorectal Carcinoma   \n",
       "18                                                                                             The Effect of Physical Exercise in a Cold Air Environment on Normal Volunteers and Asthmatic Patients   \n",
       "19                                                                                                                                                         Prostate Advances in Comparative Evidence   \n",
       "20                                                                                                                                                A Novel Analgesia Technique for ACL Reconstruction   \n",
       "21                                                                                                                          Swedish Iodine in Pregnancy and Development in Children (SWIDDICH) Study   \n",
       "22                                                                                                                              Shrunken Pore Syndrome: a Retrospective, Single Center, Cohort Study   \n",
       "23                                                                                                    Effect of Treatment With the Ablative Fractional Carbodioxide Laser in Vulvar Lichen Sclerosis   \n",
       "24                                                                                                         Intubation with Different Angled Intubation Tubes Using C-macr D Blade Videolaringoscope;   \n",
       "\n",
       "                                                                                                                                                                                              officialTitle  \\\n",
       "0   A Randomized Double-blind Crossover Study to Assess the Safety and Pharmacokinetics of Two Different Doses of Weekly Intravenous Administration of Alpha1-Proteinase Inhibitor (Human) Prolastin®-C ...   \n",
       "1   A PHASE 2A, RANDOMIZED, DOUBLE BLIND (SPONSOR-OPEN), PLACEBO CONTROLLED, PARALLEL GROUP STUDY TO ASSESS THE PHARMACODYNAMICS, SAFETY AND TOLERABILITY OF PF-05221304 AND PF-06865571 CO-ADMINISTERED...   \n",
       "2                     NUTRItional Adequacy Therapeutic Enhancement in the Critically Ill: A Randomized Double Blind, Placebo-controlled Trial of the Motilin Receptor Agonist GSK962040. The NUTRIATE Study   \n",
       "3                                                                                                                                                      The Effect of Depth of Anesthesia on Implicit Memory   \n",
       "4                                                                                                                                             Randomized Controlled Trial of Puerarin for Obesity Treatment   \n",
       "5                                                                                            The Influence of Topical Capsaicin on Thermoregulatory and Perceptual Outcomes During Exercise Within the Heat   \n",
       "6                An Open-label Dose-finding Study to Evaluate the Pharmacodynamic (PD) Profiles and Efficacy of Different Dosing Regimens of Leuprolide Oral Tablets (Ovarest®) in Women With Endometriosis   \n",
       "7                                                                                                          The Effect Of Fluvastatin XL® Treatment On The Lipid Profile In Patients With Metabolic Syndrome   \n",
       "8                                                                                              Evaluation of the Protective Efficacy of a Vaccine Derived From the Synthetic CS Protein of Plasmodium Vivax   \n",
       "9   Exploring B-Type Natriuretic Peptide (BNP) Evolution, From the Neonatal to Adolescent Period, as a Tool to Early Identify the Risk for Metabolic Syndrome (MetS) in a Former Preterm and Full Term A...   \n",
       "10                                         The Effect of Vitamin D3 Therapy on 25(OH)D, 1,25(OH)2D, VDBP, and 24,25(OH)2D Maternal Serum Levels in Pregnant Women With Vitamin D Deficient and Insufficient   \n",
       "11  A Multi-center, Randomized, Double-blind, Crossover Study to Assess the Safety and Pharmacokinetics of Liquid Alpha₁-Proteinase Inhibitor (Human) Compared to Prolastin®-C in Subjects With Alpha₁-A...   \n",
       "12  A Single-blinded, Randomised Controlled Trial Comparing the Use of Intravaginal Laser Therapy to Sham in Post-menopausal Women with Recurrent Urinary Tract Infections (rUTI) and the Impact on the ...   \n",
       "13                           A Multicentric Phase III Study in Patients With CLL B and C < 60 Years Not Treated: 6 Montly CHOP + 6 CHOP Every 3 Months Versus 3 Montly CHOP + Intensification and Autograft   \n",
       "14                                                                                                                                                The Effect of Music on Patients in Critical Care (EMPIRE)   \n",
       "15                                                                     Precision Medicine Against Type 2 Diabetes: Genetic Prediction and Nutritional Intervention With Postbiotics to Modulate Microbiota.   \n",
       "16                                                                                                                                            Stroke Prevention in the Wisconsin Native American Population   \n",
       "17  Multicentre, Randomized Clinical Trial to Evaluate Safety and Efficacy of Hyperthermic Intra-peritoneal Chemotherapy (HIPEC) With Mitomycin C Used During Surgery for Treatment of Locally Advanced ...   \n",
       "18                                                                                                    The Effect of Physical Exercise in a Cold Air Environment on Normal Volunteers and Asthmatic Patients   \n",
       "19                         International Randomised Study of Prostatectomy vs Stereotactic Body Radiotherapy (SBRT) and Conventionally Fractionated Radiotherapy vs SBRT for Organ-Confined Prostate Cancer   \n",
       "20                                             A Randomized Controlled Trial to Evaluate a Novel Analgesia Technique for ACL Reconstruction: Adductor Canal Block With an IPACK Versus Adductor Canal Block   \n",
       "21                    The Importance of Iodine During Pregnancy for Future Brain Function : a Randomized Placebo-controlled Trial. Swedish Iodine in Pregnancy and Development in Children (SWIDDICH) Study   \n",
       "22                                                                                                                                 Shrunken Pore Syndrome's Effect on Mortality in Elective Cardiac Surgery   \n",
       "23                                                                                                           Effect of Treatment With the Ablative Fractional Carbodioxide Laser in Vulvar Lichen Sclerosis   \n",
       "24  Intubation with Different Angled Intubation Tubes Using C-macr D Blade Videolaringoscope; Evaluation of the Effect on Post-operative Sore Throat, Ease and Time of Intubation, Hoarseness, Subglotti...   \n",
       "\n",
       "            overallStatus       studyType          phases  enrollment  \\\n",
       "0               COMPLETED  INTERVENTIONAL          PHASE2          30   \n",
       "1               COMPLETED  INTERVENTIONAL          PHASE2          99   \n",
       "2              TERMINATED  INTERVENTIONAL          PHASE2          91   \n",
       "3               COMPLETED  INTERVENTIONAL              NA          70   \n",
       "4      NOT_YET_RECRUITING  INTERVENTIONAL          PHASE2          80   \n",
       "5               COMPLETED  INTERVENTIONAL          PHASE4          12   \n",
       "6                 UNKNOWN  INTERVENTIONAL          PHASE2          16   \n",
       "7               COMPLETED  INTERVENTIONAL          PHASE4         614   \n",
       "8               COMPLETED  INTERVENTIONAL          PHASE2          32   \n",
       "9              RECRUITING   OBSERVATIONAL            None          70   \n",
       "10                UNKNOWN  INTERVENTIONAL  PHASE2, PHASE3          52   \n",
       "11              COMPLETED  INTERVENTIONAL  PHASE2, PHASE3          32   \n",
       "12  ACTIVE_NOT_RECRUITING  INTERVENTIONAL              NA          48   \n",
       "13              COMPLETED  INTERVENTIONAL          PHASE3         140   \n",
       "14                UNKNOWN  INTERVENTIONAL              NA          30   \n",
       "15             RECRUITING  INTERVENTIONAL              NA         158   \n",
       "16              COMPLETED  INTERVENTIONAL              NA         120   \n",
       "17                UNKNOWN  INTERVENTIONAL          PHASE3         200   \n",
       "18              COMPLETED  INTERVENTIONAL              NA          45   \n",
       "19  ACTIVE_NOT_RECRUITING  INTERVENTIONAL          PHASE3        2205   \n",
       "20              COMPLETED  INTERVENTIONAL          PHASE4          78   \n",
       "21  ACTIVE_NOT_RECRUITING  INTERVENTIONAL              NA        1337   \n",
       "22              COMPLETED   OBSERVATIONAL            None        4719   \n",
       "23                UNKNOWN  INTERVENTIONAL              NA          64   \n",
       "24              COMPLETED  INTERVENTIONAL              NA          54   \n",
       "\n",
       "   leadSponsor conditions interventions   startDate completionDate  \n",
       "0         None                              2010-11        2012-01  \n",
       "1         None                           2019-01-04     2019-10-11  \n",
       "2         None                           2014-04-04     2016-07-08  \n",
       "3         None                              2006-03        2012-01  \n",
       "4         None                           2025-08-01     2029-12-31  \n",
       "5         None                           2022-05-25     2022-10-01  \n",
       "6         None                           2022-03-18        2022-05  \n",
       "7         None                              2006-09        2007-10  \n",
       "8         None                              2014-08        2017-07  \n",
       "9         None                           2024-05-08     2025-12-31  \n",
       "10        None                           2021-04-01     2023-11-30  \n",
       "11        None                              2014-10        2016-01  \n",
       "12        None                           2023-10-01     2026-10-08  \n",
       "13        None                              1999-01        2006-03  \n",
       "14        None                           2021-04-13     2021-10-04  \n",
       "15        None                           2025-01-09     2025-12-20  \n",
       "16        None                           2021-04-14     2025-10-01  \n",
       "17        None                           2015-11-16        2024-03  \n",
       "18        None                           2019-06-03     2020-05-30  \n",
       "19        None                           2012-08-07        2027-12  \n",
       "20        None                           2017-10-04     2020-04-16  \n",
       "21        None                              2012-11        2032-06  \n",
       "22        None                           2010-01-01     2019-01-10  \n",
       "23        None                           2020-01-01        2021-12  \n",
       "24        None                           2021-03-15     2022-06-13  "
      ]
     },
     "execution_count": 14,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "ctg_query = '(\"carbon 60\" OR C60 OR buckminsterfullerene OR fullerene)'\n",
    "df_ctg = ctg_search_df(ctg_query, n=25)\n",
    "df_ctg"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 15,
   "id": "ced457f0",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>nctId</th>\n",
       "      <th>briefTitle</th>\n",
       "      <th>officialTitle</th>\n",
       "      <th>overallStatus</th>\n",
       "      <th>studyType</th>\n",
       "      <th>phases</th>\n",
       "      <th>enrollment</th>\n",
       "      <th>leadSponsor</th>\n",
       "      <th>conditions</th>\n",
       "      <th>interventions</th>\n",
       "      <th>startDate</th>\n",
       "      <th>completionDate</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>NCT00996840</td>\n",
       "      <td>SB-681323 IV for Subjects at Risk of Acute Lung Injury or ARDS</td>\n",
       "      <td>Assessment of the Anti-Inflammatory Activity, Efficacy and Safety of Intravenous SB-681323 in Subjects at Risk for Development of Acute Lung Injury (ALI) or Acute Respiratory Distress Syndrome (AR...</td>\n",
       "      <td>COMPLETED</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "      <td>PHASE2</td>\n",
       "      <td>77.0</td>\n",
       "      <td>None</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>2009-10-16</td>\n",
       "      <td>2013-02-09</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>NCT00005674</td>\n",
       "      <td>Clinical Trial of Creatine in Amyotrophic Lateral Sclerosis [ALS]</td>\n",
       "      <td>None</td>\n",
       "      <td>COMPLETED</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "      <td>PHASE2</td>\n",
       "      <td>NaN</td>\n",
       "      <td>None</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>NCT04207359</td>\n",
       "      <td>Effects of Creatine Supplementation in Breast Cancer Survivors</td>\n",
       "      <td>The THRIVE Study: An Open-Label Randomized Trial of Exercise ± Creatine Supplementation to Augment the Adaptations of Exercise Training in Breast Cancer Survivors</td>\n",
       "      <td>COMPLETED</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "      <td>NA</td>\n",
       "      <td>20.0</td>\n",
       "      <td>None</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>2020-09-30</td>\n",
       "      <td>2023-03-07</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>NCT02771808</td>\n",
       "      <td>Haptoglobin Polymorphism as a Determinant of Adverse Outcome After Cardiac Surgery in Diabetic Patients</td>\n",
       "      <td>Haptoglobin Polymorphism as a Determinant of Adverse Outcome After Cardiac Surgery in Diabetic Patients</td>\n",
       "      <td>COMPLETED</td>\n",
       "      <td>OBSERVATIONAL</td>\n",
       "      <td>None</td>\n",
       "      <td>83.0</td>\n",
       "      <td>None</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>2010-09</td>\n",
       "      <td>2015-05</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>NCT06599697</td>\n",
       "      <td>The MIGHT Trial - An Exploratory Clinical Trial of IVIG in Anti-HMGCR Immune Mediated Necrotizing Myopathy</td>\n",
       "      <td>The MIGHT Trial - An Exploratory Clinical Trial of Intravenous Immunoglobulin (IVIG) in Anti-3-Hydroxy-3-Methylglutaryl-CoA Reductase (HMGCR) Immune Mediated Necrotizing Myopathy (IMNM)</td>\n",
       "      <td>RECRUITING</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "      <td>PHASE2</td>\n",
       "      <td>12.0</td>\n",
       "      <td>None</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>2025-10-27</td>\n",
       "      <td>2027-06-30</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>5</th>\n",
       "      <td>NCT07152197</td>\n",
       "      <td>Effects of Resistance Exercises in Hereditary Sensory-Motor Neuropathy (Charcot-Marie-Tooth Disease)</td>\n",
       "      <td>Effects of a Resistance Exercise Training Program on Skeletal Muscle Quality, Functional Capacity, and Quality of Life in Young Individuals With and Without Hereditary Sensorimotor Polyneuropathy</td>\n",
       "      <td>RECRUITING</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "      <td>NA</td>\n",
       "      <td>22.0</td>\n",
       "      <td>None</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>2025-09-20</td>\n",
       "      <td>2026-09-20</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>6</th>\n",
       "      <td>NCT00758810</td>\n",
       "      <td>Impact at One Year of a Secondary Prevention Educational Program on Cardiovascular Risk Factors</td>\n",
       "      <td>Impact at One Year of a Secondary Prevention Educational Program on Cardiovascular Risk Factors, Daily Physical Activity, Dietary Habits and Blood Glucose and Fatty Acids in Coronary Syndromes Pat...</td>\n",
       "      <td>COMPLETED</td>\n",
       "      <td>OBSERVATIONAL</td>\n",
       "      <td>None</td>\n",
       "      <td>354.0</td>\n",
       "      <td>None</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>2006-10</td>\n",
       "      <td>2009-06</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>7</th>\n",
       "      <td>NCT04764448</td>\n",
       "      <td>A Study of Belcesiran in Patients With AATLD</td>\n",
       "      <td>A Phase 2, Randomized, Double-blind, Placebo-Controlled Study Investigating Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Two Dose Levels of Belcesiran in Patients With Alpha-1 An...</td>\n",
       "      <td>TERMINATED</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "      <td>PHASE2</td>\n",
       "      <td>16.0</td>\n",
       "      <td>None</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>2021-02-12</td>\n",
       "      <td>2024-05-29</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>8</th>\n",
       "      <td>NCT05537948</td>\n",
       "      <td>Efficacy and Safety of Pitavastatin and PCSK9 Inhibitors in Liver Transplant Patients</td>\n",
       "      <td>Efficacy and Safety of Pitavastatin and PCSK9 Inhibitors in Liver Transplant Patients</td>\n",
       "      <td>ACTIVE_NOT_RECRUITING</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "      <td>PHASE4</td>\n",
       "      <td>59.0</td>\n",
       "      <td>None</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>2021-10-01</td>\n",
       "      <td>2025-01-31</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>9</th>\n",
       "      <td>NCT03688958</td>\n",
       "      <td>Iodine Supplementation on Breast Cancer</td>\n",
       "      <td>Effect of Dietary Iodine Supplementation on the Proliferation of Breast Cancer</td>\n",
       "      <td>UNKNOWN</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "      <td>PHASE2</td>\n",
       "      <td>120.0</td>\n",
       "      <td>None</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>2005-03-15</td>\n",
       "      <td>2020-06</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "         nctId  \\\n",
       "0  NCT00996840   \n",
       "1  NCT00005674   \n",
       "2  NCT04207359   \n",
       "3  NCT02771808   \n",
       "4  NCT06599697   \n",
       "5  NCT07152197   \n",
       "6  NCT00758810   \n",
       "7  NCT04764448   \n",
       "8  NCT05537948   \n",
       "9  NCT03688958   \n",
       "\n",
       "                                                                                                   briefTitle  \\\n",
       "0                                              SB-681323 IV for Subjects at Risk of Acute Lung Injury or ARDS   \n",
       "1                                           Clinical Trial of Creatine in Amyotrophic Lateral Sclerosis [ALS]   \n",
       "2                                              Effects of Creatine Supplementation in Breast Cancer Survivors   \n",
       "3     Haptoglobin Polymorphism as a Determinant of Adverse Outcome After Cardiac Surgery in Diabetic Patients   \n",
       "4  The MIGHT Trial - An Exploratory Clinical Trial of IVIG in Anti-HMGCR Immune Mediated Necrotizing Myopathy   \n",
       "5        Effects of Resistance Exercises in Hereditary Sensory-Motor Neuropathy (Charcot-Marie-Tooth Disease)   \n",
       "6             Impact at One Year of a Secondary Prevention Educational Program on Cardiovascular Risk Factors   \n",
       "7                                                                A Study of Belcesiran in Patients With AATLD   \n",
       "8                       Efficacy and Safety of Pitavastatin and PCSK9 Inhibitors in Liver Transplant Patients   \n",
       "9                                                                     Iodine Supplementation on Breast Cancer   \n",
       "\n",
       "                                                                                                                                                                                             officialTitle  \\\n",
       "0  Assessment of the Anti-Inflammatory Activity, Efficacy and Safety of Intravenous SB-681323 in Subjects at Risk for Development of Acute Lung Injury (ALI) or Acute Respiratory Distress Syndrome (AR...   \n",
       "1                                                                                                                                                                                                     None   \n",
       "2                                       The THRIVE Study: An Open-Label Randomized Trial of Exercise ± Creatine Supplementation to Augment the Adaptations of Exercise Training in Breast Cancer Survivors   \n",
       "3                                                                                                  Haptoglobin Polymorphism as a Determinant of Adverse Outcome After Cardiac Surgery in Diabetic Patients   \n",
       "4                The MIGHT Trial - An Exploratory Clinical Trial of Intravenous Immunoglobulin (IVIG) in Anti-3-Hydroxy-3-Methylglutaryl-CoA Reductase (HMGCR) Immune Mediated Necrotizing Myopathy (IMNM)   \n",
       "5      Effects of a Resistance Exercise Training Program on Skeletal Muscle Quality, Functional Capacity, and Quality of Life in Young Individuals With and Without Hereditary Sensorimotor Polyneuropathy   \n",
       "6  Impact at One Year of a Secondary Prevention Educational Program on Cardiovascular Risk Factors, Daily Physical Activity, Dietary Habits and Blood Glucose and Fatty Acids in Coronary Syndromes Pat...   \n",
       "7  A Phase 2, Randomized, Double-blind, Placebo-Controlled Study Investigating Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Two Dose Levels of Belcesiran in Patients With Alpha-1 An...   \n",
       "8                                                                                                                    Efficacy and Safety of Pitavastatin and PCSK9 Inhibitors in Liver Transplant Patients   \n",
       "9                                                                                                                           Effect of Dietary Iodine Supplementation on the Proliferation of Breast Cancer   \n",
       "\n",
       "           overallStatus       studyType  phases  enrollment leadSponsor  \\\n",
       "0              COMPLETED  INTERVENTIONAL  PHASE2        77.0        None   \n",
       "1              COMPLETED  INTERVENTIONAL  PHASE2         NaN        None   \n",
       "2              COMPLETED  INTERVENTIONAL      NA        20.0        None   \n",
       "3              COMPLETED   OBSERVATIONAL    None        83.0        None   \n",
       "4             RECRUITING  INTERVENTIONAL  PHASE2        12.0        None   \n",
       "5             RECRUITING  INTERVENTIONAL      NA        22.0        None   \n",
       "6              COMPLETED   OBSERVATIONAL    None       354.0        None   \n",
       "7             TERMINATED  INTERVENTIONAL  PHASE2        16.0        None   \n",
       "8  ACTIVE_NOT_RECRUITING  INTERVENTIONAL  PHASE4        59.0        None   \n",
       "9                UNKNOWN  INTERVENTIONAL  PHASE2       120.0        None   \n",
       "\n",
       "  conditions interventions   startDate completionDate  \n",
       "0                           2009-10-16     2013-02-09  \n",
       "1                                 None           None  \n",
       "2                           2020-09-30     2023-03-07  \n",
       "3                              2010-09        2015-05  \n",
       "4                           2025-10-27     2027-06-30  \n",
       "5                           2025-09-20     2026-09-20  \n",
       "6                              2006-10        2009-06  \n",
       "7                           2021-02-12     2024-05-29  \n",
       "8                           2021-10-01     2025-01-31  \n",
       "9                           2005-03-15        2020-06  "
      ]
     },
     "execution_count": 15,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "ctg_query = '(creatine OR \"creatine monohydrate\")'\n",
    "df_ctg = ctg_search_df(ctg_query, n=25)\n",
    "df_ctg.head(10)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 24,
   "id": "0fb6c4e0",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "{\n",
      "  \"protocolSection\": {\n",
      "    \"identificationModule\": {\n",
      "      \"nctId\": \"NCT00996840\",\n",
      "      \"orgStudyIdInfo\": {\n",
      "        \"id\": \"111592\"\n",
      "      },\n",
      "      \"organization\": {\n",
      "        \"fullName\": \"GlaxoSmithKline\",\n",
      "        \"class\": \"INDUSTRY\"\n",
      "      },\n",
      "      \"briefTitle\": \"SB-681323 IV for Subjects at Risk of Acute Lung Injury or ARDS\",\n",
      "      \"officialTitle\": \"Assessment of the Anti-Inflammatory Activity, Efficacy and Safety of Intravenous SB-681323 in Subjects at Risk for Development of Acute Lung Injury (ALI) or Acute Respiratory Distress Syndrome (ARDS).\"\n",
      "    },\n",
      "    \"statusModule\": {\n",
      "      \"statusVerifiedDate\": \"2017-09\",\n",
      "      \"overallStatus\": \"COMPLETED\",\n",
      "      \"expandedAccessInfo\": {\n",
      "        \"hasExpandedAccess\": false\n",
      "      },\n",
      "      \"startDateStruct\": {\n",
      "        \"date\": \"2009-10-16\",\n",
      "        \"type\": \"ACTUAL\"\n",
      "      },\n",
      "      \"primaryCompletionDateStruct\": {\n",
      "        \"date\": \"2013-02-09\",\n",
      "        \"type\": \"ACTUAL\"\n",
      "      },\n",
      "      \"completionDateStruct\": {\n",
      "        \"date\": \"2013-02-09\",\n",
      "        \"type\": \"ACTUAL\"\n",
      "      },\n",
      "      \"studyFirstSubmitDate\": \"2009-10-15\",\n",
      "      \"studyFirstSubmitQcDate\": \"2009-10-15\",\n",
      "      \"studyFirstPostDateStruct\": {\n",
      "        \"date\": \"2009-10-16\",\n",
      "        \"type\": \"ESTIMATED\"\n",
      "      },\n",
      "      \"resultsFirstSubmitDate\": \"2017-08-04\",\n",
      "      \"resultsFirstSubmitQcDate\": \"2017-10-17\",\n",
      "      \"resultsFirstPostDateStruct\": {\n",
      "        \"date\": \"2017-10-18\",\n",
      "        \"type\": \"ACTUAL\"\n",
      "      },\n",
      "      \"dispFirstSubmitDate\": \"2015-04-27\",\n",
      "      \"dispFirstSubmitQcDate\": \"2015-04-27\",\n",
      "      \"dispFirstPostDateStruct\": {\n",
      "        \"date\": \"2015-05-13\",\n",
      "        \"type\": \"ESTIMATED\"\n",
      "      },\n",
      "      \"lastUpdateSubmitDate\": \"2017-10-17\",\n",
      "      \"lastUpdatePostDateStruct\": {\n",
      "        \"date\": \"2017-10-18\",\n",
      "        \"type\": \"ACTUAL\"\n",
      "      }\n",
      "    },\n",
      "    \"sponsorCollaboratorsModule\": {\n",
      "      \"responsibleParty\": {\n",
      "        \"type\": \"SPONSOR\"\n",
      "      },\n",
      "      \"leadSponsor\": {\n",
      "        \"name\": \"GlaxoSmithKline\",\n",
      "        \"class\": \"INDUSTRY\"\n",
      "      }\n",
      "    },\n",
      "    \"oversightModule\": {\n",
      "      \"oversightHasDmc\": true\n",
      "    },\n",
      "    \"descriptionModule\": {\n",
      "      \"briefSummary\": \"This is an early phase (Phase IIa), randomized, double-blind, parallel group, multi-centre study for subjects with trauma (physical injury) who are at risk for developing Acute Lung Injury (ALI) or Acute Respiratory Distress Syndrome (ARDS). The primary purpose of the study is to evaluate the safety and tolerability of SB-681323, which is a potent, selective inhibitor of p38 alpha (MAPK) (prevents inflammation of tissue), in comparison to a placebo.\",\n",
      "      \"detailedDescription\": \"The acute respiratory distress syndrome (ARDS) is a form of severe lung injury (ALI) characterized by hypoxemic respiratory failure (the lungs are unable to absorb oxygen to the arterial blood) and non-cardiogenic pulmonary edema (accumulation of fluid in the lungs). The syndrome may be caused by direct or indirect injury to the lungs. It is associated with a mortality rate of up to 40-50%. There are no marketed pharmacologic therapies for this devastating syndrome.\\n\\nThis study aims to assess the safety and tolerability of SB-681323, which is a potent, selective inhibitor of p38 alpha mitogen-activated protein kinase.\\n\\nThe rationale behind the development of this drug is that there are elevated levels of circulating pro-inflammatory agents, such as cytokines which are biological agents that increase levels of inflammation in the lungs. These agents are part of an 'inflammatory loop' and it may be beneficial to the condition to dampen this loop.\\n\\np38 mitogen activated protein kinase (MAPK) plays a major role in the regulation and activation of intracellular proteins which are subsequently involved in the regulation of the cytokines. The pathway is activated by 'stress', such as injury, causing the inflammation. Therefore, 'dampening' this system should reduce the level of inflammation.\\n\\nThis study will investigate the anti-inflammatory activity, efficacy (effectiveness at achieving the desired effect) and safety of SB-681323.\\n\\nTo measure the efficacy of the drug, biomarkers will be measured. Biomarkers are biological agents in the body that are effected by the presence of specific injury or inflammation and are directly or indirectly linked to a regulatory system of event in the body. They are used to measure for the presence and severity of the condition in question. This study will investigate biomarkers linked directly or indirectly to the p38 alpha regulatory mechanism/system. We will be measuring biomarkers such as serum inflammatory biomarkers, coagulation (blood clotting) system biomarkers, biomarkers of endothelial cell / neutrophil interaction and biomarkers of lung epithelial cell injury.\"\n",
      "    },\n",
      "    \"conditionsModule\": {\n",
      "      \"conditions\": [\n",
      "        \"Lung Injury, Acute\"\n",
      "      ],\n",
      "      \"keywords\": [\n",
      "        \"dilmapimod\",\n",
      "        \"p38\",\n",
      "        \"SB-681323\",\n",
      "        \"Acute Lung Injury (ALI)\",\n",
      "        \"Acute Respiratory Distress Syndrome (ARDS)\"\n",
      "      ]\n",
      "    },\n",
      "    \"designModule\": {\n",
      "      \"studyType\": \"INTERVENTIONAL\",\n",
      "      \"phases\": [\n",
      "        \"PHASE2\"\n",
      "      ],\n",
      "      \"designInfo\": {\n",
      "        \"allocation\": \"RANDOMIZED\",\n",
      "        \"interventionModel\": \"PARALLEL\",\n",
      "        \"primaryPurpose\": \"TREATMENT\",\n",
      "        \"maskingInfo\": {\n",
      "          \"masking\": \"TRIPLE\",\n",
      "          \"whoMasked\": [\n",
      "            \"PARTICIPANT\",\n",
      "            \"CARE_PROVIDER\",\n",
      "            \"INVESTIGATOR\"\n",
      "          ]\n",
      "        }\n",
      "      },\n",
      "      \"enrollmentInfo\": {\n",
      "        \"count\": 77,\n",
      "        \"type\": \"ACTUAL\"\n",
      "      }\n",
      "    },\n",
      "    \"armsInterventionsModule\": {\n",
      "      \"armGroups\": [\n",
      "        {\n",
      "          \"label\": \"Cohort 1 - SB-681323 Intravenous 3mg\",\n",
      "          \"type\": \"EXPERIMENTAL\",\n",
      "          \"description\": \"3mg SB-681323 Intravenous administration, infused over 4 hours\",\n",
      "          \"interventionNames\": [\n",
      "            \"Drug: SB-681323 Intravenous 3mg\"\n",
      "          ]\n",
      "        },\n",
      "        {\n",
      "          \"label\": \"Cohort 2 - SB-681323 Intravenous 7.5 mg\",\n",
      "          \"type\": \"EXPERIMENTAL\",\n",
      "          \"description\": \"7.5 mg SB-681323 Intravenous administration infused over 24 hours\",\n",
      "          \"interventionNames\": [\n",
      "            \"Drug: SB-681323 Intravenous 7.5 mg\"\n",
      "          ]\n",
      "        },\n",
      "        {\n",
      "          \"label\": \"Cohort 3 - SB-681323 Intravenous 7.5mg\",\n",
      "          \"type\": \"EXPERIMENTAL\",\n",
      "          \"description\": \"7.5 mg SB-681323 Intravenous administration infused over 4 hours\",\n",
      "          \"interventionNames\": [\n",
      "            \"Drug: SB-681323 Intravenous 7.5mg\"\n",
      "          ]\n",
      "        },\n",
      "        {\n",
      "          \"label\": \"Cohort 4 - SB-681323 Intravenous 10mg\",\n",
      "          \"type\": \"EXPERIMENTAL\",\n",
      "          \"description\": \"10 mg SB-681323 Intravenous administration infused over 24 hours\",\n",
      "          \"interventionNames\": [\n",
      "            \"Drug: SB-681323 Intravenous 10mg\"\n",
      "          ]\n",
      "        },\n",
      "        {\n",
      "          \"label\": \"Combined Placebo\",\n",
      "          \"type\": \"EXPERIMENTAL\",\n",
      "          \"description\": \"Placebo to match intervention\",\n",
      "          \"interventionNames\": [\n",
      "            \"Other: Placebo\"\n",
      "          ]\n",
      "        }\n",
      "      ],\n",
      "      \"interventions\": [\n",
      "        {\n",
      "          \"type\": \"DRUG\",\n",
      "          \"name\": \"SB-681323 Intravenous 3mg\",\n",
      "          \"description\": \"3 mg SB-681323 Intravenous administration infused over 4 hours\",\n",
      "          \"armGroupLabels\": [\n",
      "            \"Cohort 1 - SB-681323 Intravenous 3mg\"\n",
      "          ]\n",
      "        },\n",
      "        {\n",
      "          \"type\": \"DRUG\",\n",
      "          \"name\": \"SB-681323 Intravenous 7.5 mg\",\n",
      "          \"description\": \"7.5 mg SB-681323 Intravenous administration infused over 24 hours\",\n",
      "          \"armGroupLabels\": [\n",
      "            \"Cohort 2 - SB-681323 Intravenous 7.5 mg\"\n",
      "          ]\n",
      "        },\n",
      "        {\n",
      "          \"type\": \"DRUG\",\n",
      "          \"name\": \"SB-681323 Intravenous 7.5mg\",\n",
      "          \"description\": \"7.5 mg SB-681323 Intravenous administration infused over 4 hours\",\n",
      "          \"armGroupLabels\": [\n",
      "            \"Cohort 3 - SB-681323 Intravenous 7.5mg\"\n",
      "          ]\n",
      "        },\n",
      "        {\n",
      "          \"type\": \"DRUG\",\n",
      "          \"name\": \"SB-681323 Intravenous 10mg\",\n",
      "          \"description\": \"10 mg SB-681323 Intravenous administration infused over 24 hours\",\n",
      "          \"armGroupLabels\": [\n",
      "            \"Cohort 4 - SB-681323 Intravenous 10mg\"\n",
      "          ]\n",
      "        },\n",
      "        {\n",
      "          \"type\": \"OTHER\",\n",
      "          \"name\": \"Placebo\",\n",
      "          \"description\": \"Placebo to match intervention\",\n",
      "          \"armGroupLabels\": [\n",
      "            \"Combined Placebo\"\n",
      "          ]\n",
      "        }\n",
      "      ]\n",
      "    },\n",
      "    \"outcomesModule\": {\n",
      "      \"primaryOutcomes\": [\n",
      "        {\n",
      "          \"measure\": \"Mean Hematology Parameters Basophils, Eosinophils, Lymphocytes, Monocytes, Total Neutrophils, Platelet Count, White Blood Cell Count\",\n",
      "          \"description\": \"Mean hematology parameters including basophils, eosinophils, lymphocytes, monocytes, total neutrophils, platelet count, white blood cell count were reported. If sample for hematology test had been obtained for standard of care within ± 4 h of the planned assessment then it was not collected at the planned assessment time point.\",\n",
      "          \"timeFrame\": \"\\\"Day 2, pre-dose\\\", \\\"Day 3, pre-dose\\\", \\\"Day 3, 24 h\\\" and \\\"Follow up (Day 7)\\\"\"\n",
      "        },\n",
      "        {\n",
      "          \"measure\": \"Mean Hematology Parameters- Hemoglobin, Mean Corpuscle Hemoglobin Concentration (MCHC)\",\n",
      "          \"description\": \"Mean hematology parameters including hemoglobin, MCHC were reported. If sample for hematology test had been obtained for standard of care within ± 4 h of the planned assessment then it was not collected at the planned assessment time point.\",\n",
      "          \"timeFrame\": \"\\\"Day 2, pre-dose\\\", \\\"Day 3, pre-dose\\\", \\\"Day 3, 24 h\\\" and \\\"Follow up (Day 7)\\\"\"\n",
      "        },\n",
      "        {\n",
      "          \"measure\": \"Mean Hematology Parameters- Mean Corpuscle Hemoglobin\",\n",
      "          \"description\": \"Hematology parameter mean corpuscle hemoglobin was reported. If sample for hematology test had been obtained for standard of care within ± 4 h of the planned assessment then it was not collected at the planned assessment time point.\",\n",
      "          \"timeFrame\": \"\\\"Day 2, pre-dose\\\", \\\"Day 3, pre-dose\\\", \\\"Day 3, 24 h\\\" and \\\"Follow up (Day 7)\\\"\"\n",
      "        },\n",
      "        {\n",
      "          \"measure\": \"Hematology Parameters-Mean Corpuscle Volume\",\n",
      "          \"description\": \"Absolute values of mean corpuscle volume were reported. If sample for hematology test had been obtained for standard of care within ± 4 h of the planned assessment then it was not collected at the planned assessment time point.\",\n",
      "          \"timeFrame\": \"\\\"Day 2, pre-dose\\\", \\\"Day 3, pre-dose\\\", \\\"Day 3, 24 h\\\" and \\\"Follow up (Day 7)\\\"\"\n",
      "        },\n",
      "        {\n",
      "          \"measure\": \"Mean Hematology Parameters-reticulocytes, Red Blood Cell Count\",\n",
      "          \"description\": \"Absolute values of reticulocytes and red blood cell count were reported. If sample for hematology test had been obtained for standard of care within ± 4 h of the planned assessment then it was not collected at the planned assessment time point.\",\n",
      "          \"timeFrame\": \"\\\"Day 2, pre-dose\\\", \\\"Day 3, pre-dose\\\", \\\"Day 3, 24 h\\\" and \\\"Follow up (Day 7)\\\"\"\n",
      "        },\n",
      "        {\n",
      "          \"measure\": \"Mean Clinical Chemistry Parameters- Albumin and Total Protein\",\n",
      "          \"description\": \"Absolute values of albumin and total protein were reported. If sample for clinical chemistry test had been obtained for standard of care within ± 4 h of the planned assessment then it was not collected at the planned assessment time point.\",\n",
      "          \"timeFrame\": \"\\\"Day 2, pre-dose\\\", \\\"Day 3, pre-dose\\\", \\\"Day 3, 24 h\\\" and \\\"Follow up (Day 7)\\\"\"\n",
      "        },\n",
      "        {\n",
      "          \"measure\": \"Mean Clinical Chemistry Parameters-alkaline Phosphatase, Alanine Amino Transferase, Aspartate Amino Transferase, Creatine Kinase and Gamma Glutamyl Transferase\",\n",
      "          \"description\": \"Absolute values of alkaline phosphatase, alanine amino transferase, aspartate amino transferase, creatine kinase and gamma glutamyl transferase were reported. If sample for clinical chemistry test had been obtained for standard of care within ± 4 h of the planned assessment then it was not collected at the planned assessment time point.\",\n",
      "          \"timeFrame\": \"\\\"Day 2, pre-dose\\\", \\\"Day 3, pre-dose\\\", \\\"Day 3, 24 h\\\" and \\\"Follow up (Day 7)\\\"\"\n",
      "        },\n",
      "        {\n",
      "          \"measure\": \"Mean Clinical Chemistry Parameters- Direct Bilirubin, Total Bilirubin, Creatinine and Uric Acid\",\n",
      "          \"description\": \"Absolute values of direct bilirubin, total bilirubin, creatinine and uric acid were reported. If sample for clinical chemistry test had been obtained for standard of care within ± 4 h of the planned assessment then it was not collected at the planned assessment time point.\",\n",
      "          \"timeFrame\": \"\\\"Day 2, pre-dose\\\", \\\"Day 3, pre-dose\\\", \\\"Day 3, 24 h\\\" and \\\"Follow up (Day 7)\\\"\"\n",
      "        },\n",
      "        {\n",
      "          \"measure\": \"Mean Clinical Chemistry Parameters- Calcium, Chloride, Glucose, Bicarbonate, Potassium, Sodium and Ratio of Urea to Blood Urea Nitrogen (Urea/BUN)\",\n",
      "          \"description\": \"Absolute values of calcium, chloride, glucose, bicarbonate, potassium, sodium and Urea/BUN were reported. If sample for clinical chemistry test had been obtained for standard of care within ± 4 h of the planned assessment then it was not collected at the planned assessment time point.\",\n",
      "          \"timeFrame\": \"\\\"Day 2, pre-dose\\\", \\\"Day 3, pre-dose\\\", \\\"Day 3, 24 h\\\" and \\\"Follow up (Day 7)\\\"\"\n",
      "        },\n",
      "        {\n",
      "          \"measure\": \"Mean Clinical Chemistry Parameters-estradiol\",\n",
      "          \"description\": \"Absolute values of Estradiol were reported. If sample for clinical chemistry test had been obtained for standard of care within ± 4 h of the planned assessment then it was not collected at the planned assessment time point.\",\n",
      "          \"timeFrame\": \"Day 1 (pre-dose) and Day 3 (24 h)\"\n",
      "        },\n",
      "        {\n",
      "          \"measure\": \"Mean Clinical Chemistry Parameters-Blood pH at Screening\",\n",
      "          \"description\": \"Absolute values of Blood pH at screening were reported as clinical chemistry parameter.\",\n",
      "          \"timeFrame\": \"Screening\"\n",
      "        },\n",
      "        {\n",
      "          \"measure\": \"Vital Parameter- Mean Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP)\",\n",
      "          \"description\": \"Absolute values of SBP and DBP were reported.\",\n",
      "          \"timeFrame\": \"For Cohort 1 and 3: \\\"Day 1, 4 h\\\", \\\"Day 2, pre-dose\\\", \\\"Day 3, pre-dose and 24 h\\\" and \\\"Follow up (Day 7)\\\"; for Cohort 2 and 4: \\\"Day 2, pre-dose\\\", \\\"Day 3, pre-dose and 24 h\\\", and \\\"Follow up (Day 7)\\\"\"\n",
      "        },\n",
      "        {\n",
      "          \"measure\": \"Vital Parameter: Mean Heart Rate\",\n",
      "          \"description\": \"Absolute values of mean heart rate were reported.\",\n",
      "          \"timeFrame\": \"For Cohort 1 and 3: \\\"Day 1, 4 h\\\", \\\"Day 2, pre-dose\\\", \\\"Day 3, pre-dose and 24 h\\\" and \\\"Follow up (Day 7)\\\"; for Cohort 2 and 4: \\\"Day 2, pre-dose\\\", \\\"Day 3, pre-dose and 24 h\\\", and \\\"Follow up (Day 7)\\\"\"\n",
      "        },\n",
      "        {\n",
      "          \"measure\": \"Vital Sign: Mean Percent Oxygen (O2) in Blood\",\n",
      "          \"description\": \"Absolute values of mean percent O2 in blood were reported.\",\n",
      "          \"timeFrame\": \"For Cohort 1 and 3: \\\"Day 1, 4 h\\\", \\\"Day 2, pre-dose\\\", \\\"Day 3, pre-dose and 24 h\\\" and \\\"Follow up (Day 7)\\\"; for Cohort 2 and 4: \\\"Day 2, pre-dose\\\", \\\"Day 3, pre-dose and 24 h\\\", and \\\"Follow up (Day 7)\\\"\"\n",
      "        },\n",
      "        {\n",
      "          \"measure\": \"Vital Signs: Mean Oxygen Saturation (SaO2) Via Pulse Oximetry\",\n",
      "          \"description\": \"Assessment of SaO2 via pulse oximetry was planned for cohort 1 and 3 at Day 1 (4 h), Day 2 (pre-dose) and Day 3 (pre-dose and 24 h) and for cohort 2 and 4: Day 2 (pre-dose) and Day 3 (pre-dose and 24 h). However, the analyzable data was not collected for this parameter.\",\n",
      "          \"timeFrame\": \"For Cohort 1 and 3: \\\"Day 1, 4 h\\\", \\\"Day 2, pre-dose\\\", \\\"Day 3, pre-dose and 24 h\\\"; for Cohort 2 and 4: \\\"Day 2, pre-dose\\\", and \\\"Day 3, pre-dose and 24 h\\\"\"\n",
      "        },\n",
      "        {\n",
      "          \"measure\": \"Vital Signs: Mean Level of Positive End Expiratory Pressure\",\n",
      "          \"description\": \"Assessment of level of positive end expiratory pressure was planned for cohort 1 and 3 at Day 1 (4 h), Day 2 (pre-dose) and Day 3 (pre-dose and 24 h) and for cohort 2 and 4: Day 2 (pre-dose) and Day 3 (pre-dose and 24 h). However, the analyzable data was not collected for this parameter.\",\n",
      "          \"timeFrame\": \"For Cohort 1 and 3: \\\"Day 1, 4 h\\\", \\\"Day 2, pre-dose\\\", \\\"Day 3, pre-dose and 24 h\\\"; for Cohort 2 and 4: \\\"Day 2, pre-dose\\\", and \\\"Day 3, pre-dose and 24 h\\\"\"\n",
      "        },\n",
      "        {\n",
      "          \"measure\": \"Vital Signs: Mean Level of Peak and Plateau Ventilator Pressures\",\n",
      "          \"description\": \"Assessment of mean level of peak and plateau ventilator pressures was planned for cohort 1 and 3 at Day 1 (4 h), Day 2 (pre-dose) and Day 3 (pre-dose and 24 h) and for cohort 2 and 4: Day 2 (pre-dose) and Day 3 (pre-dose and 24 h). However, the analyzable data was not collected for this parameter.\",\n",
      "          \"timeFrame\": \"For Cohort 1 and 3: \\\"Day 1, 4 h\\\", \\\"Day 2, pre-dose\\\", \\\"Day 3, pre-dose and 24 h\\\"; for Cohort 2 and 4: \\\"Day 2, pre-dose\\\", and \\\"Day 3, pre-dose and 24 h\\\"\"\n",
      "        },\n",
      "        {\n",
      "          \"measure\": \"Vital Signs: Mean Oxygen Requirement (FiO2) Via Pulse Oximetry\",\n",
      "          \"description\": \"Assessment of mean FiO2 via pulse oximetry was planned for cohort 1 and 3 at Day 1 (4 h), Day 2 (pre-dose) and Day 3 (pre-dose and 24 h) and for cohort 2 and 4: Day 2 (pre-dose) and Day 3 (pre-dose and 24 h). However, the analyzable data was not collected for this parameter.\",\n",
      "          \"timeFrame\": \"For Cohort 1 and 3: \\\"Day 1, 4 h\\\", \\\"Day 2, pre-dose\\\", \\\"Day 3, pre-dose and 24 h\\\"; for Cohort 2 and 4: \\\"Day 2, pre-dose\\\", and \\\"Day 3, pre-dose and 24 h\\\"\"\n",
      "        },\n",
      "        {\n",
      "          \"measure\": \"Mean Electrocardiogram (ECG) Parameters Including PR, QRS, QT, and QTcB, QTcF, RR Intervals\",\n",
      "          \"description\": \"12-lead ECGs were obtained at each timepoint during the study using an ECG machine that automatically calculated the heart rate and measures RR, PR, QRS, QT, and QTc intervals. Absolute mean values of PR, QRS, QT, and QTcB, QTcF, RR intervals were reported.\",\n",
      "          \"timeFrame\": \"Day 2, pre-dose, Day 3, pre-dose, Day 3, 24 h and Follow-up (Day 7)\"\n",
      "        },\n",
      "        {\n",
      "          \"measure\": \"Number of Participants With Any Adverse Events (AE) and Serious Adverse Events (SAE)\",\n",
      "          \"description\": \"AE was defined as any untoward medical occurrence in a participant temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. SAE include AEs those result in death, a life-threatening AE, inpatient hospitalization or prolongation of existing hospitalization, a persistent or significant incapacity or substantial disruption of the ability to conduct normal functions, or a congenital anomaly/birth defect. Important medical events that may not result in death, be life-threatening, or require hospitalization may be considered serious when, based upon appropriate medical judgment, they may jeopardize the participant and may require medical or surgical intervention to prevent one of the outcomes listed in this definition.\",\n",
      "          \"timeFrame\": \"Up to Follow-up (Day 7)\"\n",
      "        }\n",
      "      ],\n",
      "      \"secondaryOutcomes\": [\n",
      "        {\n",
      "          \"measure\": \"Mean Serum Interleukin-6 Levels\",\n",
      "          \"description\": \"Serum samples were collected at 6, 12, 18, 24, 48, 72 and 96 h since first dose on Day 1. Mean absolute values of Serum interleukin-6 levels at these specified time oints were reported.\",\n",
      "          \"timeFrame\": \"6, 12, 18, 24, 48, 72 and 96 h since first dose on Day 1\"\n",
      "        },\n",
      "        {\n",
      "          \"measure\": \"Mean Serum CXCL8 (Interleuin-8) Levels\",\n",
      "          \"description\": \"Serum samples were collected at 6, 12, 18, 24, 48, 72 and 96 h since first dose on Day 1. Mean absolute values of Serum CXCL8 (Interleuin-8) levels at these specified time points were reported.\",\n",
      "          \"timeFrame\": \"6, 12, 18, 24, 48, 72 and 96 h since first dose on Day 1\"\n",
      "        },\n",
      "        {\n",
      "          \"measure\": \"Mean Serum C-Reactive Protein (CRP) Levels\",\n",
      "          \"description\": \"Serum samples were collected at 6, 12, 18, 24, 48, 72 and 96 h since first dose on Day 1. Mean absolute values of serum CRP levels at these specified time points were reported.\",\n",
      "          \"timeFrame\": \"6, 12, 18, 24, 48, 72 and 96 h since first dose on Day 1\"\n",
      "        },\n",
      "        {\n",
      "          \"measure\": \"Markers of Endothelial Cell/Neutrophil Interaction: Mean Soluble Tumor Necrosis Factor Receptors-I\",\n",
      "          \"description\": \"Samples were collected at 6, 12, 18, 24, 48, 72 and 96 h since first dose on Day 1. Mean absolute values of soluble tumor necrosis factor receptors-I levels at these specified time points were reported.\",\n",
      "          \"timeFrame\": \"6, 12, 18, 24, 48, 72 and 96 h since first dose on Day 1\"\n",
      "        },\n",
      "        {\n",
      "          \"measure\": \"Markers of Lung Epithelial Cell Injury: Mean Myeloperoxidase (MPO) Levels\",\n",
      "          \"description\": \"Serum samples were collected at 6, 12, 18, 24, 48, 72 and 96 h since first dose on Day 1. Mean absolute values of MPO levels at these specified time points were reported.\",\n",
      "          \"timeFrame\": \"6, 12, 18, 24, 48, 72 and 96 h since first dose on Day 1\"\n",
      "        },\n",
      "        {\n",
      "          \"measure\": \"Mean Area Under the Concentration-time Curve From Zero (Pre-dose) to 24 Hours (AUC0-24)\",\n",
      "          \"description\": \"Absolute values of the mean AUC 0-24 of SB-681323 were reported. PK samples were collected for cohort 1 and 3 at Day 1 (pre-dose, 4, 4.25, 5, 6, 8, 12, 18h), Day 2 (pre-dose and 4h), Day 3 (0, 4, 24, 48h) and for cohort 2 and 4 at Day 1 (pre-dose), Day (pre-dose), Day 3 (pre-dose, 24h10minutes \\\\[min\\\\], 24h45min, 27, 34, 40, 80 h since doing on Day 3).\",\n",
      "          \"timeFrame\": \"For cohort 1 and 3: Day 1 (pre-dose, 4, 4.25, 5, 6, 8, 12, 18h), Day 2 (pre-dose and 4h), Day 3 (0, 4, 24, 48h). For cohort 2 and 4: Day 1 (pre-dose), Day (pre-dose), Day 3 (pre-dose)\"\n",
      "        },\n",
      "        {\n",
      "          \"measure\": \"Mean Average Concentration (Cavg) of SB-681323\",\n",
      "          \"description\": \"Absolute values of mean Cavg of SB-681323 were reported. PK samples were collected for cohort 1 and 3 at Day 1 (pre-dose, 4, 4.25, 5, 6, 8, 12, 18h), Day 2 (pre-dose and 4h), Day 3 (0, 4, 24, 48h) and for cohort 2 and 4 at Day 1 (pre-dose), Day (pre-dose), Day 3 (pre-dose, 24h 10 min, 24h 45min, 27, 34, 40, 80 h since doing on Day 3).\",\n",
      "          \"timeFrame\": \"For cohort 1 and 3: Day 1 (pre-dose, 4, 4.25, 5, 6, 8, 12, 18h), Day 2 (pre-dose and 4h), Day 3 (0, 4, 24, 48h). For cohort 2 and 4: Day 1 (pre-dose), Day (pre-dose), Day 3 (pre-dose, 24h 10minutes [min], 24h 45min, 27, 34, 40, 80 h since doing on Day 3)\"\n",
      "        },\n",
      "        {\n",
      "          \"measure\": \"Maximum Observed Concentration (Cmax) of SB-681323\",\n",
      "          \"description\": \"Absolute values of the Cmax of SB-681323 were reported. PK samples were collected for cohort 1 and 3 at Day 1 (pre-dose, 4, 4.25, 5, 6, 8, 12, 18h), Day 2 (pre-dose and 4h), Day 3 (0, 4, 24, 48h) and for cohort 2 and 4 at Day 1 (pre-dose), Day (pre-dose), Day 3 (pre-dose, 24h 10 min, 24h 45min, 27, 34, 40, 80 h since doing on Day 3).\",\n",
      "          \"timeFrame\": \"For cohort 1 and 3: Day 1 (pre-dose, 4, 4.25, 5, 6, 8, 12, 18h), Day 2 (pre-dose and 4h), Day 3 (0, 4, 24, 48h). For cohort 2 and 4: Day 1 (pre-dose), Day (pre-dose), Day 3 (pre-dose, 24h 10 min, 24h 45min, 27, 34, 40, 80 h since doing on Day 3)\"\n",
      "        }\n",
      "      ]\n",
      "    },\n",
      "    \"eligibilityModule\": {\n",
      "      \"eligibilityCriteria\": \"Inclusion Criteria:\\n\\nA subject will be eligible for inclusion in this study only if all of the following criteria apply:\\n\\n* Male or female, 18 - 80 years of age (inclusive) with major trauma admitted to the Intensive Care Unit (ICU).\\n* Injury Severity score (ISS) \\\\>16 to \\\\<70 (exclusive)\\n* A female subject is eligible to participate if she is of non-child-bearing potential or of:\\n* Child-bearing potential and agrees to use one of the approved contraception methods (oral contraceptive, either combined or progesterone alone, injectable progesterone, implants of levonorgestrel, estrogenic vaginal ring, percutaneous contraceptive patches, intrauterine device (IUD) or intrauterine system (IUS) with less than 1% non-effectiveness, documented male partner sterilization, double barrier method, i.e. condom and occlusive cap plus spermicidal agent) for an appropriate period of time (as determined by the product label or investigator, if applicable. Female subjects must agree to use contraception until one week post-last dose, if applicable.\\n* Male subjects must agree to use one of the approved contraception methods (abstinence, defined as sexual inactivity consistent with the preferred and usual lifestyle of the subject, condom during non-vaginal intercourse with any partner (male or female), condom and occlusive cap plus spermicidal agent during sexual intercourse with a female) if applicable. This criterion must be followed from the time of the first dose of study medication until one week post-last dose, if applicable.\\n* BMI within the range 19.0 - 35.0 kg/m2 inclusive (clinical estimate of height and weight is acceptable).\\n* The subject or legal decision maker is capable of giving written informed consent, which includes compliance with the requirements and restrictions listed in the consent form.\\n* QTcB or QTcF \\\\< 450 msec; or QTc \\\\< 480 msec in subjects with Bundle Branch Block.\\n* The subject must be randomized into the study within 24-26 hours from the time of trauma.\\n\\nExclusion Criteria:\\n\\nA subject will not be eligible for inclusion in this study if any of the following criteria apply:\\n\\n* Known positive Hepatitis B surface antigen or Hepatitis C antibody.\\n* Known positive test for HIV antibody.\\n* A known history of substance abuse, alcohol abuse, or regular alcohol consumption within 6 months of the study defined as:\\n* an average weekly intake of greater than 21 units or an average daily intake of greater than 3 units (males), or defined as an average weekly intake of greater than 14 units or an average daily intake of greater than 2 units (females). One unit is equivalent to a half-pint (220mL) of beer or 1 (25ml) measure of spirits or 1 glass (125ml) of wine.\\n* The subject has participated in a clinical trial and has received an investigational product within the following time period prior to the first dosing day in the current study: 30 days, 5 half-lives or twice the duration of the biological effect of the investigational product (whichever is longer).\\n* History of sensitivity to any of the study medications, or components thereof, or a history of drug or other allergy that, in the opinion of the investigator or GSK Medical Monitor, contraindicates their participation.\\n* Haemoglobin \\\\< 7g/dL.\\n* Pregnant females as determined by positive serum or urine hCG test prior to dosing.\\n* Lactating females.\\n* Unwillingness or inability to follow the procedures outlined in the protocol.\\n* History of sensitivity to heparin or heparin-induced thrombocytopenia.\\n* Diagnosis of ALI at admission.\\n* Head trauma (Abbreviated Injury Score \\\\[AIS\\\\]\\\\>3), liver trauma (AIS\\\\>2), or trauma that in the opinion of the Principle Investigator or GSK medical monitor is deemed unsurvivable.\\n* Known history of neuromuscular disease or cord injury at C5 or above.\\n* Elevated ALT or AST \\\\> 1.5 ULN.\\n* History of bone marrow or solid organ transplant.\\n* Known history of auto-immune disorder in which immunosuppressive agents, other than prednisone, were required within the last 6 weeks.\\n* Known to be receiving oral or intravenous corticosteroids within 7 days of admission.\\n* Subject with active tuberculosis or being treated for active tuberculosis.\\n* Known history of malignancy within the past 5 years with the exception of successfully treated squamous cell or basal cell cancer of the skin.\\n* Arterial blood pH less than 7.1 or serum HCO3 - \\\\<15 before infusion is started.\\n* Persistent cardiovascular instability requiring therapy with more than one vasopressor.\\n* A patient will be excluded if in the judgement of the Principle Investigator or GSK medical monitor their participation could jeopardize the health of the subject or the integrity of the study.\",\n",
      "      \"healthyVolunteers\": false,\n",
      "      \"sex\": \"ALL\",\n",
      "      \"minimumAge\": \"18 Years\",\n",
      "      \"maximumAge\": \"80 Years\",\n",
      "      \"stdAges\": [\n",
      "        \"ADULT\",\n",
      "        \"OLDER_ADULT\"\n",
      "      ]\n",
      "    },\n",
      "    \"contactsLocationsModule\": {\n",
      "      \"overallOfficials\": [\n",
      "        {\n",
      "          \"name\": \"GSK Clinical Trials\",\n",
      "          \"affiliation\": \"GlaxoSmithKline\",\n",
      "          \"role\": \"STUDY_DIRECTOR\"\n",
      "        }\n",
      "      ],\n",
      "      \"locations\": [\n",
      "        {\n",
      "          \"facility\": \"GSK Investigational Site\",\n",
      "          \"city\": \"Lexington\",\n",
      "          \"state\": \"Kentucky\",\n",
      "          \"zip\": \"40536-0293\",\n",
      "          \"country\": \"United States\",\n",
      "          \"geoPoint\": {\n",
      "            \"lat\": 37.98869,\n",
      "            \"lon\": -84.47772\n",
      "          }\n",
      "        },\n",
      "        {\n",
      "          \"facility\": \"GSK Investigational Site\",\n",
      "          \"city\": \"Durham\",\n",
      "          \"state\": \"North Carolina\",\n",
      "          \"zip\": \"27710\",\n",
      "          \"country\": \"United States\",\n",
      "          \"geoPoint\": {\n",
      "            \"lat\": 35.99403,\n",
      "            \"lon\": -78.89862\n",
      "          }\n",
      "        },\n",
      "        {\n",
      "          \"facility\": \"GSK Investigational Site\",\n",
      "          \"city\": \"Winston-Salem\",\n",
      "          \"state\": \"North Carolina\",\n",
      "          \"zip\": \"27157\",\n",
      "          \"country\": \"United States\",\n",
      "          \"geoPoint\": {\n",
      "            \"lat\": 36.09986,\n",
      "            \"lon\": -80.24422\n",
      "          }\n",
      "        },\n",
      "        {\n",
      "          \"facility\": \"GSK Investigational Site\",\n",
      "          \"city\": \"Philadelphia\",\n",
      "          \"state\": \"Pennsylvania\",\n",
      "          \"zip\": \"19104\",\n",
      "          \"country\": \"United States\",\n",
      "          \"geoPoint\": {\n",
      "            \"lat\": 39.95238,\n",
      "            \"lon\": -75.16362\n",
      "          }\n",
      "        },\n",
      "        {\n",
      "          \"facility\": \"GSK Investigational Site\",\n",
      "          \"city\": \"Pittsburgh\",\n",
      "          \"state\": \"Pennsylvania\",\n",
      "          \"zip\": \"15213\",\n",
      "          \"country\": \"United States\",\n",
      "          \"geoPoint\": {\n",
      "            \"lat\": 40.44062,\n",
      "            \"lon\": -79.99589\n",
      "          }\n",
      "        },\n",
      "        {\n",
      "          \"facility\": \"GSK Investigational Site\",\n",
      "          \"city\": \"Nashville\",\n",
      "          \"state\": \"Tennessee\",\n",
      "          \"zip\": \"37232-7110\",\n",
      "          \"country\": \"United States\",\n",
      "          \"geoPoint\": {\n",
      "            \"lat\": 36.16589,\n",
      "            \"lon\": -86.78444\n",
      "          }\n",
      "        }\n",
      "      ]\n",
      "    },\n",
      "    \"referencesModule\": {\n",
      "      \"references\": [\n",
      "        {\n",
      "          \"pmid\": \"26102252\",\n",
      "          \"type\": \"DERIVED\",\n",
      "          \"citation\": \"Christie JD, Vaslef S, Chang PK, May AK, Gunn SR, Yang S, Hardes K, Kahl L, Powley WM, Lipson DA, Bayliffe AI, Lazaar AL. A Randomized Dose-Escalation Study of the Safety and Anti-Inflammatory Activity of the p38 Mitogen-Activated Protein Kinase Inhibitor Dilmapimod in Severe Trauma Subjects at Risk for Acute Respiratory Distress Syndrome. Crit Care Med. 2015 Sep;43(9):1859-69. doi: 10.1097/CCM.0000000000001132.\"\n",
      "        }\n",
      "      ],\n",
      "      \"seeAlsoLinks\": [\n",
      "        {\n",
      "          \"label\": \"Researchers can use this site to request access to anonymised patient level data and/or supporting documents from clinical studies to conduct further research.\",\n",
      "          \"url\": \"https://www.clinicalstudydatarequest.com\"\n",
      "        }\n",
      "      ],\n",
      "      \"availIpds\": [\n",
      "        {\n",
      "          \"id\": \"111592\",\n",
      "          \"type\": \"Dataset Specification\",\n",
      "          \"url\": \"https://www.clinicalstudydatarequest.com\",\n",
      "          \"comment\": \"For additional information about this study please refer to the GSK Clinical Study Register\"\n",
      "        },\n",
      "        {\n",
      "          \"id\": \"111592\",\n",
      "          \"type\": \"Clinical Study Report\",\n",
      "          \"url\": \"https://www.clinicalstudydatarequest.com\",\n",
      "          \"comment\": \"For additional information about this study please refer to the GSK Clinical Study Register\"\n",
      "        },\n",
      "        {\n",
      "          \"id\": \"111592\",\n",
      "          \"type\": \"Informed Consent Form\",\n",
      "          \"url\": \"https://www.clinicalstudydatarequest.com\",\n",
      "          \"comment\": \"For additional information about this study please refer to the GSK Clinical Study Register\"\n",
      "        },\n",
      "        {\n",
      "          \"id\": \"111592\",\n",
      "          \"type\": \"Study Protocol\",\n",
      "          \"url\": \"https://www.clinicalstudydatarequest.com\",\n",
      "          \"comment\": \"For additional information about this study please refer to the GSK Clinical Study Register\"\n",
      "        },\n",
      "        {\n",
      "          \"id\": \"111592\",\n",
      "          \"type\": \"Individual Participant Data Set\",\n",
      "          \"url\": \"https://www.clinicalstudydatarequest.com\",\n",
      "          \"comment\": \"For additional information about this study please refer to the GSK Clinical Study Register\"\n",
      "        },\n",
      "        {\n",
      "          \"id\": \"111592\",\n",
      "          \"type\": \"Statistical Analysis Plan\",\n",
      "          \"url\": \"https://www.clinicalstudydatarequest.com\",\n",
      "          \"comment\": \"For additional information about this study please refer to the GSK Clinical Study Register\"\n",
      "        },\n",
      "        {\n",
      "          \"id\": \"111592\",\n",
      "          \"type\": \"Annotated Case Report Form\",\n",
      "          \"url\": \"https://www.clinicalstudydatarequest.com\",\n",
      "          \"comment\": \"For additional information about this study please refer to the GSK Clinical Study Register\"\n",
      "        }\n",
      "      ]\n",
      "    },\n",
      "    \"ipdSharingStatementModule\": {\n",
      "      \"ipdSharing\": \"YES\",\n",
      "      \"description\": \"Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.\"\n",
      "    }\n",
      "  },\n",
      "  \"resultsSection\": {\n",
      "    \"participantFlowModule\": {\n",
      "      \"preAssignmentDetails\": \"Seventy seven participants were randomized in the study and were included in All subject population.\",\n",
      "      \"recruitmentDetails\": \"This study was conducted across 6 centers in the United States, with 5 centers actually enrolling participants. The first participant was enrolled on 16-October-2009 and the last participant completed the study on 09-February-2013.\",\n",
      "      \"groups\": [\n",
      "        {\n",
      "          \"id\": \"FG000\",\n",
      "          \"title\": \"Combined Placebo\",\n",
      "          \"description\": \"Eligible participants received matching placebo intravenous (IV) infusion over 4 hours (h) or 24 h for 3 days\"\n",
      "        },\n",
      "        {\n",
      "          \"id\": \"FG001\",\n",
      "          \"title\": \"Cohort 1-SB-681323, 3 mg, 4 h\",\n",
      "          \"description\": \"Eligible participants received SB-681323, 3 milligrams (mg), IV infusion over 4h for 3 days\"\n",
      "        },\n",
      "        {\n",
      "          \"id\": \"FG002\",\n",
      "          \"title\": \"Cohort 2-SB-681323, 7.5 mg, 24 h\",\n",
      "          \"description\": \"Eligible participants received SB-681323, 7.5 mg, IV infusion over 24h for 3 days\"\n",
      "        },\n",
      "        {\n",
      "          \"id\": \"FG003\",\n",
      "          \"title\": \"Cohort 3-SB-681323, 7.5 mg, 4 h\",\n",
      "          \"description\": \"Eligible participants received SB-681323, 7.5 mg, IV infusion over 4h for 3 days\"\n",
      "        },\n",
      "        {\n",
      "          \"id\": \"FG004\",\n",
      "          \"title\": \"Cohort 4-SB-681323, 10 mg, 24 h\",\n",
      "          \"description\": \"Eligible participants received SB-681323, 10 mg, IV infusion over 24h for 3 days\"\n",
      "        }\n",
      "      ],\n",
      "      \"periods\": [\n",
      "        {\n",
      "          \"title\": \"Overall Study\",\n",
      "          \"milestones\": [\n",
      "            {\n",
      "              \"type\": \"STARTED\",\n",
      "              \"achievements\": [\n",
      "                {\n",
      "                  \"groupId\": \"FG000\",\n",
      "                  \"numSubjects\": \"20\"\n",
      "                },\n",
      "                {\n",
      "                  \"groupId\": \"FG001\",\n",
      "                  \"numSubjects\": \"9\"\n",
      "                },\n",
      "                {\n",
      "                  \"groupId\": \"FG002\",\n",
      "                  \"numSubjects\": \"12\"\n",
      "                },\n",
      "                {\n",
      "                  \"groupId\": \"FG003\",\n",
      "                  \"numSubjects\": \"18\"\n",
      "                },\n",
      "                {\n",
      "                  \"groupId\": \"FG004\",\n",
      "                  \"numSubjects\": \"18\"\n",
      "                }\n",
      "              ]\n",
      "            },\n",
      "            {\n",
      "              \"type\": \"COMPLETED\",\n",
      "              \"achievements\": [\n",
      "                {\n",
      "                  \"groupId\": \"FG000\",\n",
      "                  \"numSubjects\": \"19\"\n",
      "                },\n",
      "                {\n",
      "                  \"groupId\": \"FG001\",\n",
      "                  \"numSubjects\": \"7\"\n",
      "                },\n",
      "                {\n",
      "                  \"groupId\": \"FG002\",\n",
      "                  \"numSubjects\": \"11\"\n",
      "                },\n",
      "                {\n",
      "                  \"groupId\": \"FG003\",\n",
      "                  \"numSubjects\": \"17\"\n",
      "                },\n",
      "                {\n",
      "                  \"groupId\": \"FG004\",\n",
      "                  \"numSubjects\": \"16\"\n",
      "                }\n",
      "              ]\n",
      "            },\n",
      "            {\n",
      "              \"type\": \"NOT COMPLETED\",\n",
      "              \"achievements\": [\n",
      "                {\n",
      "                  \"groupId\": \"FG000\",\n",
      "                  \"numSubjects\": \"1\"\n",
      "                },\n",
      "                {\n",
      "                  \"groupId\": \"FG001\",\n",
      "                  \"numSubjects\": \"2\"\n",
      "                },\n",
      "                {\n",
      "                  \"groupId\": \"FG002\",\n",
      "                  \"numSubjects\": \"1\"\n",
      "                },\n",
      "                {\n",
      "                  \"groupId\": \"FG003\",\n",
      "                  \"numSubjects\": \"1\"\n",
      "                },\n",
      "                {\n",
      "                  \"groupId\": \"FG004\",\n",
      "                  \"numSubjects\": \"2\"\n",
      "                }\n",
      "              ]\n",
      "            }\n",
      "          ],\n",
      "          \"dropWithdraws\": [\n",
      "            {\n",
      "              \"type\": \"Adverse Event\",\n",
      "              \"reasons\": [\n",
      "                {\n",
      "                  \"groupId\": \"FG000\",\n",
      "                  \"numSubjects\": \"0\"\n",
      "                },\n",
      "                {\n",
      "                  \"groupId\": \"FG001\",\n",
      "                  \"numSubjects\": \"1\"\n",
      "                },\n",
      "                {\n",
      "                  \"groupId\": \"FG002\",\n",
      "                  \"numSubjects\": \"0\"\n",
      "                },\n",
      "                {\n",
      "                  \"groupId\": \"FG003\",\n",
      "                  \"numSubjects\": \"0\"\n",
      "                },\n",
      "                {\n",
      "                  \"groupId\": \"FG004\",\n",
      "                  \"numSubjects\": \"0\"\n",
      "                }\n",
      "              ]\n",
      "            },\n",
      "            {\n",
      "              \"type\": \"Physician Decision\",\n",
      "              \"reasons\": [\n",
      "                {\n",
      "                  \"groupId\": \"FG000\",\n",
      "                  \"numSubjects\": \"0\"\n",
      "                },\n",
      "                {\n",
      "                  \"groupId\": \"FG001\",\n",
      "                  \"numSubjects\": \"0\"\n",
      "                },\n",
      "                {\n",
      "                  \"groupId\": \"FG002\",\n",
      "                  \"numSubjects\": \"1\"\n",
      "                },\n",
      "                {\n",
      "                  \"groupId\": \"FG003\",\n",
      "                  \"numSubjects\": \"1\"\n",
      "                },\n",
      "                {\n",
      "                  \"groupId\": \"FG004\",\n",
      "                  \"numSubjects\": \"2\"\n",
      "                }\n",
      "              ]\n",
      "            },\n",
      "            {\n",
      "              \"type\": \"Withdrawal by Subject\",\n",
      "              \"reasons\": [\n",
      "                {\n",
      "                  \"groupId\": \"FG000\",\n",
      "                  \"numSubjects\": \"1\"\n",
      "                },\n",
      "                {\n",
      "                  \"groupId\": \"FG001\",\n",
      "                  \"numSubjects\": \"1\"\n",
      "                },\n",
      "                {\n",
      "                  \"groupId\": \"FG002\",\n",
      "                  \"numSubjects\": \"0\"\n",
      "                },\n",
      "                {\n",
      "                  \"groupId\": \"FG003\",\n",
      "                  \"numSubjects\": \"0\"\n",
      "                },\n",
      "                {\n",
      "                  \"groupId\": \"FG004\",\n",
      "                  \"numSubjects\": \"0\"\n",
      "                }\n",
      "              ]\n",
      "            }\n",
      "          ]\n",
      "        }\n",
      "      ]\n",
      "    },\n",
      "    \"baselineCharacteristicsModule\": {\n",
      "      \"groups\": [\n",
      "        {\n",
      "          \"id\": \"BG000\",\n",
      "          \"title\": \"Combined Placebo\",\n",
      "          \"description\": \"Eligible participants received matching placebo IV infusion over 4 h or 24 h for 3 days\"\n",
      "        },\n",
      "        {\n",
      "          \"id\": \"BG001\",\n",
      "          \"title\": \"Cohort 1-SB-681323, 3 mg, 4 h\",\n",
      "          \"description\": \"Eligible participants received SB-681323, 3 mg, IV infusion over 4h for 3 days\"\n",
      "        },\n",
      "        {\n",
      "          \"id\": \"BG002\",\n",
      "          \"title\": \"Cohort 2-SB-681323, 7.5 mg, 24 h\",\n",
      "          \"description\": \"Eligible participants received SB-681323, 7.5 mg, IV infusion over 24h for 3 days\"\n",
      "        },\n",
      "        {\n",
      "          \"id\": \"BG003\",\n",
      "          \"title\": \"Cohort 3-SB-681323, 7.5 mg, 4 h\",\n",
      "          \"description\": \"Eligible participants received SB-681323, 7.5 mg, IV infusion over 4h for 3 days\"\n",
      "        },\n",
      "        {\n",
      "          \"id\": \"BG004\",\n",
      "          \"title\": \"Cohort 4-SB-681323, 10 mg, 24 h\",\n",
      "          \"description\": \"Eligible participants received SB-681323, 10 mg, IV infusion over 24h for 3 days\"\n",
      "        },\n",
      "        {\n",
      "          \"id\": \"BG005\",\n",
      "          \"title\": \"Total\",\n",
      "          \"description\": \"Total of all reporting groups\"\n",
      "        }\n",
      "      ],\n",
      "      \"denoms\": [\n",
      "        {\n",
      "          \"units\": \"Participants\",\n",
      "          \"counts\": [\n",
      "            {\n",
      "              \"groupId\": \"BG000\",\n",
      "              \"value\": \"20\"\n",
      "            },\n",
      "            {\n",
      "              \"groupId\": \"BG001\",\n",
      "              \"value\": \"9\"\n",
      "            },\n",
      "            {\n",
      "              \"groupId\": \"BG002\",\n",
      "              \"value\": \"12\"\n",
      "            },\n",
      "            {\n",
      "              \"groupId\": \"BG003\",\n",
      "              \"value\": \"18\"\n",
      "            },\n",
      "            {\n",
      "              \"groupId\": \"BG004\",\n",
      "              \"value\": \"18\"\n",
      "            },\n",
      "            {\n",
      "              \"groupId\": \"BG005\",\n",
      "              \"value\": \"77\"\n",
      "            }\n",
      "          ]\n",
      "        }\n",
      "      ],\n",
      "      \"measures\": [\n",
      "        {\n",
      "          \"title\": \"Age, Continuous\",\n",
      "          \"paramType\": \"MEAN\",\n",
      "          \"dispersionType\": \"STANDARD_DEVIATION\",\n",
      "          \"unitOfMeasure\": \"Years\",\n",
      "          \"classes\": [\n",
      "            {\n",
      "              \"categories\": [\n",
      "                {\n",
      "                  \"measurements\": [\n",
      "                    {\n",
      "                      \"groupId\": \"BG000\",\n",
      "                      \"value\": \"41.2\",\n",
      "                      \"spread\": \"17.70\"\n",
      "                    },\n",
      "                    {\n",
      "                      \"groupId\": \"BG001\",\n",
      "                      \"value\": \"47.4\",\n",
      "                      \"spread\": \"19.31\"\n",
      "                    },\n",
      "                    {\n",
      "                      \"groupId\": \"BG002\",\n",
      "                      \"value\": \"34.5\",\n",
      "                      \"spread\": \"15.61\"\n",
      "                    },\n",
      "                    {\n",
      "                      \"groupId\": \"BG003\",\n",
      "                      \"value\": \"44.1\",\n",
      "                      \"spread\": \"15.89\"\n",
      "                    },\n",
      "                    {\n",
      "                      \"groupId\": \"BG004\",\n",
      "                      \"value\": \"46.1\",\n",
      "                      \"spread\": \"21.80\"\n",
      "                    },\n",
      "                    {\n",
      "                      \"groupId\": \"BG005\",\n",
      "                      \"value\": \"42.7\",\n",
      "                      \"spread\": \"18.24\"\n",
      "                    }\n",
      "                  ]\n",
      "                }\n",
      "              ]\n",
      "            }\n",
      "          ]\n",
      "        },\n",
      "        {\n",
      "          \"title\": \"Sex: Female, Male\",\n",
      "          \"paramType\": \"COUNT_OF_PARTICIPANTS\",\n",
      "          \"unitOfMeasure\": \"Participants\",\n",
      "          \"classes\": [\n",
      "            {\n",
      "              \"categories\": [\n",
      "                {\n",
      "                  \"title\": \"Female\",\n",
      "                  \"measurements\": [\n",
      "                    {\n",
      "                      \"groupId\": \"BG000\",\n",
      "                      \"value\": \"3\"\n",
      "                    },\n",
      "                    {\n",
      "                      \"groupId\": \"BG001\",\n",
      "                      \"value\": \"3\"\n",
      "                    },\n",
      "                    {\n",
      "                      \"groupId\": \"BG002\",\n",
      "                      \"value\": \"1\"\n",
      "                    },\n",
      "                    {\n",
      "                      \"groupId\": \"BG003\",\n",
      "                      \"value\": \"4\"\n",
      "                    },\n",
      "                    {\n",
      "                      \"groupId\": \"BG004\",\n",
      "                      \"value\": \"5\"\n",
      "                    },\n",
      "                    {\n",
      "                      \"groupId\": \"BG005\",\n",
      "                      \"value\": \"16\"\n",
      "                    }\n",
      "                  ]\n",
      "                },\n",
      "                {\n",
      "                  \"title\": \"Male\",\n",
      "                  \"measurements\": [\n",
      "                    {\n",
      "                      \"groupId\": \"BG000\",\n",
      "                      \"value\": \"17\"\n",
      "                    },\n",
      "                    {\n",
      "                      \"groupId\": \"BG001\",\n",
      "                      \"value\": \"6\"\n",
      "                    },\n",
      "                    {\n",
      "                      \"groupId\": \"BG002\",\n",
      "                      \"value\": \"11\"\n",
      "                    },\n",
      "                    {\n",
      "                      \"groupId\": \"BG003\",\n",
      "                      \"value\": \"14\"\n",
      "                    },\n",
      "                    {\n",
      "                      \"groupId\": \"BG004\",\n",
      "                      \"value\": \"13\"\n",
      "                    },\n",
      "                    {\n",
      "                      \"groupId\": \"BG005\",\n",
      "                      \"value\": \"61\"\n",
      "                    }\n",
      "                  ]\n",
      "                }\n",
      "              ]\n",
      "            }\n",
      "          ]\n",
      "        },\n",
      "        {\n",
      "          \"title\": \"Race (NIH/OMB)\",\n",
      "          \"paramType\": \"COUNT_OF_PARTICIPANTS\",\n",
      "          \"unitOfMeasure\": \"Participants\",\n",
      "          \"classes\": [\n",
      "            {\n",
      "              \"categories\": [\n",
      "                {\n",
      "                  \"title\": \"American Indian or Alaska Native\",\n",
      "                  \"measurements\": [\n",
      "                    {\n",
      "                      \"groupId\": \"BG000\",\n",
      "                      \"value\": \"0\"\n",
      "                    },\n",
      "                    {\n",
      "                      \"groupId\": \"BG001\",\n",
      "                      \"value\": \"0\"\n",
      "                    },\n",
      "                    {\n",
      "                      \"groupId\": \"BG002\",\n",
      "                      \"value\": \"0\"\n",
      "                    },\n",
      "                    {\n",
      "                      \"groupId\": \"BG003\",\n",
      "                      \"value\": \"1\"\n",
      "                    },\n",
      "                    {\n",
      "                      \"groupId\": \"BG004\",\n",
      "                      \"value\": \"0\"\n",
      "                    },\n",
      "                    {\n",
      "                      \"groupId\": \"BG005\",\n",
      "                      \"value\": \"1\"\n",
      "                    }\n",
      "                  ]\n",
      "                },\n",
      "                {\n",
      "                  \"title\": \"Asian\",\n",
      "                  \"measurements\": [\n",
      "                    {\n",
      "                      \"groupId\": \"BG000\",\n",
      "                      \"value\": \"0\"\n",
      "                    },\n",
      "                    {\n",
      "                      \"groupId\": \"BG001\",\n",
      "                      \"value\": \"0\"\n",
      "                    },\n",
      "                    {\n",
      "                      \"groupId\": \"BG002\",\n",
      "                      \"value\": \"0\"\n",
      "                    },\n",
      "                    {\n",
      "                      \"groupId\": \"BG003\",\n",
      "                      \"value\": \"0\"\n",
      "                    },\n",
      "                    {\n",
      "                      \"groupId\": \"BG004\",\n",
      "                      \"value\": \"0\"\n",
      "                    },\n",
      "                    {\n",
      "                      \"groupId\": \"BG005\",\n",
      "                      \"value\": \"0\"\n",
      "                    }\n",
      "                  ]\n",
      "                },\n",
      "                {\n",
      "                  \"title\": \"Native Hawaiian or Other Pacific Islander\",\n",
      "                  \"measurements\": [\n",
      "                    {\n",
      "                      \"groupId\": \"BG000\",\n",
      "                      \"value\": \"0\"\n",
      "                    },\n",
      "                    {\n",
      "                      \"groupId\": \"BG001\",\n",
      "                      \"value\": \"0\"\n",
      "                    },\n",
      "                    {\n",
      "                      \"groupId\": \"BG002\",\n",
      "                      \"value\": \"0\"\n",
      "                    },\n",
      "                    {\n",
      "                      \"groupId\": \"BG003\",\n",
      "                      \"value\": \"0\"\n",
      "                    },\n",
      "                    {\n",
      "                      \"groupId\": \"BG004\",\n",
      "                      \"value\": \"0\"\n",
      "                    },\n",
      "                    {\n",
      "                      \"groupId\": \"BG005\",\n",
      "                      \"value\": \"0\"\n",
      "                    }\n",
      "                  ]\n",
      "                },\n",
      "                {\n",
      "                  \"title\": \"Black or African American\",\n",
      "                  \"measurements\": [\n",
      "                    {\n",
      "                      \"groupId\": \"BG000\",\n",
      "                      \"value\": \"8\"\n",
      "                    },\n",
      "                    {\n",
      "                      \"groupId\": \"BG001\",\n",
      "                      \"value\": \"0\"\n",
      "                    },\n",
      "                    {\n",
      "                      \"groupId\": \"BG002\",\n",
      "                      \"value\": \"3\"\n",
      "                    },\n",
      "                    {\n",
      "                      \"groupId\": \"BG003\",\n",
      "                      \"value\": \"3\"\n",
      "                    },\n",
      "                    {\n",
      "                      \"groupId\": \"BG004\",\n",
      "                      \"value\": \"4\"\n",
      "                    },\n",
      "                    {\n",
      "                      \"groupId\": \"BG005\",\n",
      "                      \"value\": \"18\"\n",
      "                    }\n",
      "                  ]\n",
      "                },\n",
      "                {\n",
      "                  \"title\": \"White\",\n",
      "                  \"measurements\": [\n",
      "                    {\n",
      "                      \"groupId\": \"BG000\",\n",
      "                      \"value\": \"11\"\n",
      "                    },\n",
      "                    {\n",
      "                      \"groupId\": \"BG001\",\n",
      "                      \"value\": \"9\"\n",
      "                    },\n",
      "                    {\n",
      "                      \"groupId\": \"BG002\",\n",
      "                      \"value\": \"8\"\n",
      "                    },\n",
      "                    {\n",
      "                      \"groupId\": \"BG003\",\n",
      "                      \"value\": \"12\"\n",
      "                    },\n",
      "                    {\n",
      "                      \"groupId\": \"BG004\",\n",
      "                      \"value\": \"13\"\n",
      "                    },\n",
      "                    {\n",
      "                      \"groupId\": \"BG005\",\n",
      "                      \"value\": \"53\"\n",
      "                    }\n",
      "                  ]\n",
      "                },\n",
      "                {\n",
      "                  \"title\": \"More than one race\",\n",
      "                  \"measurements\": [\n",
      "                    {\n",
      "                      \"groupId\": \"BG000\",\n",
      "                      \"value\": \"0\"\n",
      "                    },\n",
      "                    {\n",
      "                      \"groupId\": \"BG001\",\n",
      "                      \"value\": \"0\"\n",
      "                    },\n",
      "                    {\n",
      "                      \"groupId\": \"BG002\",\n",
      "                      \"value\": \"0\"\n",
      "                    },\n",
      "                    {\n",
      "                      \"groupId\": \"BG003\",\n",
      "                      \"value\": \"0\"\n",
      "                    },\n",
      "                    {\n",
      "                      \"groupId\": \"BG004\",\n",
      "                      \"value\": \"0\"\n",
      "                    },\n",
      "                    {\n",
      "                      \"groupId\": \"BG005\",\n",
      "                      \"value\": \"0\"\n",
      "                    }\n",
      "                  ]\n",
      "                },\n",
      "                {\n",
      "                  \"title\": \"Unknown or Not Reporte\n"
     ]
    }
   ],
   "source": [
    "# --- Cell 9: Fetch full record (pick an nctId from df_ctg first) ---\n",
    "if not df_ctg.empty:\n",
    "    nct = df_ctg.loc[0, \"nctId\"]\n",
    "    study = ctg_get_study(nct)\n",
    "    pretty(study, max_len=50000)\n",
    "else:\n",
    "    print(\"No studies found for that query (try broadening terms).\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "f54639b7",
   "metadata": {},
   "outputs": [],
   "source": []
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": ".venv",
   "language": "python",
   "name": "python3"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.13.5"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 5
}
